0001628280-23-036217.txt : 20231102 0001628280-23-036217.hdr.sgml : 20231102 20231102080100 ACCESSION NUMBER: 0001628280-23-036217 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 231370159 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 10-Q 1 itci-20230930.htm 10-Q itci-20230930
000156751412-312023Q3false13600015675142023-01-012023-09-3000015675142023-10-31xbrli:shares00015675142023-09-30iso4217:USD00015675142022-12-31iso4217:USDxbrli:shares0001567514us-gaap:ProductMember2023-07-012023-09-300001567514us-gaap:ProductMember2022-07-012022-09-300001567514us-gaap:ProductMember2023-01-012023-09-300001567514us-gaap:ProductMember2022-01-012022-09-300001567514us-gaap:GrantMember2023-07-012023-09-300001567514us-gaap:GrantMember2022-07-012022-09-300001567514us-gaap:GrantMember2023-01-012023-09-300001567514us-gaap:GrantMember2022-01-012022-09-3000015675142023-07-012023-09-3000015675142022-07-012022-09-3000015675142022-01-012022-09-300001567514us-gaap:CommonStockMember2021-12-310001567514us-gaap:AdditionalPaidInCapitalMember2021-12-310001567514us-gaap:RetainedEarningsMember2021-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100015675142021-12-310001567514us-gaap:CommonStockMember2022-01-012022-03-310001567514us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100015675142022-01-012022-03-310001567514us-gaap:RetainedEarningsMember2022-01-012022-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001567514us-gaap:CommonStockMember2022-03-310001567514us-gaap:AdditionalPaidInCapitalMember2022-03-310001567514us-gaap:RetainedEarningsMember2022-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100015675142022-03-310001567514us-gaap:CommonStockMember2022-04-012022-06-300001567514us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000015675142022-04-012022-06-300001567514us-gaap:RetainedEarningsMember2022-04-012022-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001567514us-gaap:CommonStockMember2022-06-300001567514us-gaap:AdditionalPaidInCapitalMember2022-06-300001567514us-gaap:RetainedEarningsMember2022-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000015675142022-06-300001567514us-gaap:CommonStockMember2022-07-012022-09-300001567514us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001567514us-gaap:RetainedEarningsMember2022-07-012022-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001567514us-gaap:CommonStockMember2022-09-300001567514us-gaap:AdditionalPaidInCapitalMember2022-09-300001567514us-gaap:RetainedEarningsMember2022-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000015675142022-09-300001567514us-gaap:CommonStockMember2022-12-310001567514us-gaap:AdditionalPaidInCapitalMember2022-12-310001567514us-gaap:RetainedEarningsMember2022-12-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001567514us-gaap:CommonStockMember2023-01-012023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100015675142023-01-012023-03-310001567514us-gaap:RetainedEarningsMember2023-01-012023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001567514us-gaap:CommonStockMember2023-03-310001567514us-gaap:AdditionalPaidInCapitalMember2023-03-310001567514us-gaap:RetainedEarningsMember2023-03-310001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100015675142023-03-310001567514us-gaap:CommonStockMember2023-04-012023-06-300001567514us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000015675142023-04-012023-06-300001567514us-gaap:RetainedEarningsMember2023-04-012023-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001567514us-gaap:CommonStockMember2023-06-300001567514us-gaap:AdditionalPaidInCapitalMember2023-06-300001567514us-gaap:RetainedEarningsMember2023-06-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000015675142023-06-300001567514us-gaap:CommonStockMember2023-07-012023-09-300001567514us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001567514us-gaap:RetainedEarningsMember2023-07-012023-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001567514us-gaap:CommonStockMember2023-09-300001567514us-gaap:AdditionalPaidInCapitalMember2023-09-300001567514us-gaap:RetainedEarningsMember2023-09-300001567514us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30itci:Segment0001567514us-gaap:CustomerConcentrationRiskMemberitci:ThreeMajorWholesalersMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-30xbrli:pure0001567514us-gaap:CustomerConcentrationRiskMemberitci:CustomerOneMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001567514us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberitci:CustomerTwoMember2023-01-012023-09-300001567514us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberitci:CustomerThreeMember2023-01-012023-09-300001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001567514itci:FDICCertificatesOfDepositMember2023-09-300001567514us-gaap:CertificatesOfDepositMember2023-09-300001567514us-gaap:CommercialPaperMember2023-09-300001567514us-gaap:CorporateDebtSecuritiesMember2023-09-300001567514us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001567514itci:FDICCertificatesOfDepositMember2022-12-310001567514us-gaap:CertificatesOfDepositMember2022-12-310001567514us-gaap:CommercialPaperMember2022-12-310001567514us-gaap:CorporateDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:CashAndCashEquivalentsMember2023-09-300001567514us-gaap:CashAndCashEquivalentsMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMember2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-300001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberitci:FDICCertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001567514us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001567514us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMember2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001567514us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001567514stpr:NY2018-09-300001567514us-gaap:VehiclesMember2023-09-300001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2005-05-312023-09-300001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2023-09-300001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2005-05-310001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMembersrt:MinimumMember2005-05-312005-05-310001567514us-gaap:ProductMembersrt:MaximumMemberitci:BristolMyersSquibbCompanyMember2005-05-312005-05-310001567514us-gaap:ProductMemberitci:BristolMyersSquibbCompanyMember2023-01-012023-09-300001567514us-gaap:PurchaseCommitmentMember2023-09-300001567514us-gaap:PurchaseCommitmentMember2022-12-310001567514itci:InventoriableCostsMember2023-01-012023-09-300001567514itci:InventoriableCostsMember2022-01-012022-09-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001567514us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001567514us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-3000015675142022-01-012022-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2022-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-09-300001567514itci:TimeBasedRestrictedStockUnitsRSUMember2023-09-300001567514us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001567514us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001567514us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001567514us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001567514us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001567514itci:MichaelIHalsteadMember2023-01-012023-09-300001567514itci:MichaelIHalsteadMember2023-07-012023-09-300001567514itci:MichaelIHalsteadMember2023-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 10-Q
_______________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_________to_________
Commission File Number: 001-36274
_______________________
INTRA-CELLULAR THERAPIES, INC.
(Exact name of registrant as specified in its charter)
_______________________
Delaware36-4742850
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
430 East 29th Street
New York, New York
10016
(Address of principal executive offices)(Zip Code)
(646) 440-9333
(Registrant’s telephone number, including area code)
_______________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common StockITCI
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filero
 
Non-accelerated fileroSmaller reporting companyo
 
  Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of October 31, 2023, the registrant had 96,238,126 shares of common stock outstanding.

Intra-Cellular Therapies, Inc.
Index to Form 10-Q
In this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” and the “Company” mean Intra-Cellular Therapies, Inc. and our subsidiary. “ITI” refers to our wholly-owned subsidiary ITI, Inc.
i
PART I: FINANCIAL INFORMATION
Item 1.    FINANCIAL STATEMENTS
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Balance Sheets (in thousands except share and per share amounts)
September 30,
2023		December 31,
2022
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$99,402 $148,615 
Investment securities, available-for-sale393,619 443,290 
Restricted cash1,750 1,750 
Accounts receivable, net102,670 75,189 
Inventory42,986 23,920 
Prepaid expenses and other current assets61,998 45,193 
Total current assets702,425 737,957 
Property and equipment, net1,789 1,913 
Right of use assets, net13,364 14,824 
Other assets86 86 
Total assets$717,664 $754,780 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$10,613 $10,395 
Accrued and other current liabilities27,829 19,657 
Accrued customer programs35,618 25,621 
Accrued employee benefits25,448 22,996 
Operating lease liabilities3,584 4,567 
Total current liabilities103,092 83,236 
Operating lease liabilities, non-current13,891 15,474 
Total liabilities116,983 98,710 
Stockholders’ equity:
Common stock, $0.0001 par value: 175,000,000 shares authorized at September 30, 2023 and December 31, 2022; 96,225,617 and 94,829,794 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
10 9 
Additional paid-in capital2,190,587 2,137,737 
Accumulated deficit(1,588,581)(1,477,486)
Accumulated comprehensive loss(1,335)(4,190)
Total stockholders’ equity600,681 656,070 
Total liabilities and stockholders’ equity$717,664 $754,780 
See accompanying notes to these condensed consolidated financial statements.
1
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Operations (in thousands except share and per share amounts) (Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Revenues
Product sales, net$125,810 $71,870 $330,669 $161,699 
Grant revenue363 — 1,602 746 
Total revenues, net126,173 71,870 332,271 162,445 
Operating expenses:
Cost of product sales9,129 5,850 23,043 13,655 
Selling, general and administrative105,207 88,375 305,144 264,151 
Research and development41,550 33,274 129,368 100,853 
Total operating expenses155,886 127,499 457,555 378,659 
Loss from operations(29,713)(55,629)(125,284)(216,214)
Interest income5,498 2,122 14,377 3,990 
Loss before provision for income taxes(24,215)(53,507)(110,907)(212,224)
Income tax expense(43)(1)(188)(6)
Net loss$(24,258)$(53,508)$(111,095)$(212,230)
Net loss per common share:
Basic & Diluted$(0.25)$(0.57)$(1.16)$(2.26)
Weighted average number of common shares:
Basic & Diluted96,143,08394,516,79495,745,64193,809,124
See accompanying notes to these condensed consolidated financial statements.
2
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Comprehensive Loss (in thousands) (Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net loss$(24,258)$(53,508)$(111,095)$(212,230)
Other comprehensive gain (loss):
Unrealized gain (loss) on investment securities933 (694)2,855 (5,132)
Comprehensive loss$(23,325)$(54,202)$(108,240)$(217,362)
See accompanying notes to these condensed consolidated financial statements.
3
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Stockholders’ Equity (in thousands except share and per share amounts) (Unaudited)
Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Accumulated
Comprehensive
(Loss) Income		Total
Stockholders’
Equity
SharesAmount
Balance at December 31, 202181,886,965$8 $1,639,476 $(1,221,230)$(364)$417,890 
Common shares issued January 7, 202210,952,3811 433,724 — — 433,725 
Exercise of stock options and issuances of restricted stock1,180,696— 8,089 — — 8,089 
Stock issued for services383— 24 — — 24 
Share-based compensation—— 8,105 — — 8,105 
Net loss—— — (72,119)— (72,119)
Other comprehensive loss—— — — (2,964)(2,964)
Balance at March 31, 202294,020,425$9 $2,089,418 $(1,293,349)$(3,328)$792,750 
Exercise of stock options and issuances of restricted stock346,411— 5,504 — — 5,504 
Stock issued for services397— 22 — — 22 
Share-based compensation—— 11,998 — — 11,998 
Net loss—— — (86,603)— (86,603)
Other comprehensive loss—— — — (1,474)(1,474)
Balance at June 30, 202294,367,2339 2,106,942 (1,379,952)(4,802)722,197 
Exercise of stock options and issuances of restricted stock333,954— 5,654 — — 5,654 
Stock issued for services475— 22 — — 22 
Share-based compensation—— 11,751 — — 11,751 
Net loss—— — (53,508)— (53,508)
Other comprehensive loss—— — — (694)(694)
Balance at September 30, 202294,701,662$9 $2,124,369 $(1,433,460)$(5,496)$685,422 

Balance at December 31, 202294,829,794$9 $2,137,737 $(1,477,486)$(4,190)$656,070 
Exercise of stock options and issuances of restricted stock849,8271 3,639 — — 3,640 
Stock issued for services408— 22 — — 22 
Share-based compensation—— 10,439 — — 10,439 
Net loss—— — (44,053)— (44,053)
Other comprehensive gain—— — — 1,492 1,492 
Balance at March 31, 202395,680,029$10 $2,151,837 $(1,521,539)$(2,698)$627,610 
Exercise of stock options and issuances of restricted stock402,994— 8,585 — — 8,585 
Stock issued for services364— 23 — — 23 
Share-based compensation—— 13,226 — — 13,226 
Net loss—— — (42,784)— (42,784)
Other comprehensive gain—— — — 430 430 
Balance at June 30, 202396,083,387$10 $2,173,671 $(1,564,323)$(2,268)$607,090 
Exercise of stock options and issuances of restricted stock141,780— 2,581 — — 2,581 
Stock issued for services450— 24 — — 24 
Share-based compensation—— 14,311 — — 14,311 
Net loss—— — (24,258)— (24,258)
Other comprehensive gain—— — — 933 933 
Balance at September 30, 202396,225,617$10 $2,190,587 $(1,588,581)$(1,335)$600,681 
See accompanying notes to these condensed consolidated financial statements.
4
Intra-Cellular Therapies, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited)
Nine Months Ended September 30,
20232022
Cash flows used in operating activities
Net loss$(111,095)$(212,230)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation392 513 
Share-based compensation37,976 31,854 
Stock issued for services69 68 
Amortization of premiums and accretion of discounts on investment securities, net(5,861)(717)
Changes in operating assets and liabilities:
Accounts receivable, net(27,481)(41,382)
Inventory(19,066)(15,649)
Prepaid expenses and other assets(16,805)(18,686)
Accounts payable218 5,528 
Accrued and other current liabilities8,172 3,777 
Accrued customer programs9,997 13,982 
Accrued employee benefits2,452 253 
Operating lease liabilities, net(1,106)1,696 
Net cash used in operating activities(122,138)(230,993)
Cash flows provided by (used in) investing activities
Purchases of investments(310,805)(643,707)
Maturities of investments369,192 465,877 
Purchases of property and equipment(268)(806)
Net cash provided by (used in) investing activities58,119 (178,636)
Cash flows provided by financing activities
Proceeds of public offering, net— 433,725 
Proceeds from exercise of stock options14,806 19,247 
Net cash provided by financing activities14,806 452,972 
Net (decrease) increase in cash, cash equivalents, and restricted cash
(49,213)43,343 
Cash, cash equivalents, and restricted cash at beginning of period150,365 93,765 
Cash, cash equivalents, and restricted cash at end of period$101,152 $137,108 
Non-cash investing and financing activities
Right of use assets under operating leases$— $5,375 
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:
September 30,
20232022
Cash and cash equivalents$99,402 $135,358 
Restricted cash1,750 1,750 
Total cash, cash equivalents and restricted cash$101,152 $137,108 
See accompanying notes to these condensed consolidated financial statements.
5
Intra-Cellular Therapies, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
September 30, 2023
1. Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder.
In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
Recent Accounting Pronouncements
Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
6
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of September 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the nine-month period ended September 30, 2023, 97% of sales were from three major wholesalers accounting for approximately 36%, 32%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of September 30, 2023, the Company continues to believe that such customers are of high credit quality.
3. Investment Securities
Investment securities consisted of the following (in thousands):
September 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$191,726 $4 $(692)$191,038 
FDIC Certificates of Deposit5,131 — (40)5,091 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper81,594 — (150)81,444 
Corporate Notes/Bonds76,503 — (457)76,046 
$414,954 $4 $(1,339)$413,619 
December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$188,465 $14 $(1,729)$186,750 
FDIC Certificates of Deposit4,155 3 (72)4,086 
Certificates of Deposit7,500 — — 7,500 
Commercial Paper100,711 3 (269)100,445 
Corporate Notes/Bonds189,588 1 (2,141)187,448 
$490,419 $21 $(4,211)$486,229 
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2023 and December 31, 2022, the Company held $41.2 million and $71.5 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year.
7
Unrealized losses as of September 30, 2023 approximate less than 1% of the estimated fair value of investments. The aggregate related fair value of investments with unrealized losses as of September 30, 2023 was $340.9 million, which consisted of $183.4 million from U.S. government agency securities, $5.1 million of certificates of deposit, $81.4 million of commercial paper, and $71.0 million of corporate notes/bonds. $58.9 million of the aggregate fair value of investments with unrealized losses as of September 30, 2023 has been held in a continuous unrealized loss position for over 12 months, with the remaining $282.0 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2022, the aggregate related fair value of investments with unrealized losses was $438.3 million. $49.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2022 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $389.2 million held in a continuous unrealized loss position for less than 12 months.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
4. Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company has no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2023 and December 31, 2022. The carrying value of cash held in money market funds of $4.4 million as of September 30, 2023 and $12.2 million as of December 31, 2022 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in certificates of deposit of $20.0 million as of September 30, 2023 is included in cash and cash equivalents. The carrying value of cash held in commercial paper of $14.9 million, U.S. government agency securities of $20.5 million and certificates of deposit of $7.5 million as of December 31, 2022 is included in cash and cash equivalents.
8
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
September 30,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$4,420 $4,420 $— $— 
U.S. Government Agency Securities191,038 — 191,038 — 
FDIC Certificates of Deposit5,091 — 5,091 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper81,444 — 81,444 — 
Corporate Notes/Bonds76,046 — 76,046 — 
$418,039 $4,420 $413,619 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$12,203 $12,203 $— $— 
U.S. Government Agency Securities186,750 — 186,750 — 
FDIC Certificates of Deposit4,086 — 4,086 — 
Certificates of Deposit7,500 — 7,500 — 
Commercial Paper100,445 — 100,445 — 
Corporate Notes/Bonds187,448 — 187,448 — 
$498,432 $12,203 $486,229 $— 
5. Inventory
Inventory consists of the following (in thousands):
September 30,
2023		December 31,
2022
Raw materials$33,173 $17,227 
Work in process4,773 2,594 
Finished goods5,040 4,099 
$42,986 $23,920 
The raw materials balance includes the active pharmaceutical ingredients (API) and any related intermediate compounds. This supply exceeds 12 months of forecasted sales and other needs.
9
6. Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029.
The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to obtain motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The Company has no other significant leases. In addition, no identified leases require allocations between lease and non-lease components.
The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2023 and December 31, 2022 and operating cash outflows as of September 30, 2023 and 2022 (in thousands, except years and percentages):
September 30, 2023December 31, 2022
Other information
Weighted average remaining lease term5.6 years5.9 years
Weighted average discount rate9.07 %8.76 %
Nine Months Ended September 30,
20232022
Lease cost
Operating lease cost$2,921$4,139
Variable lease cost1,1301,218
Short-term lease cost1,757—
$5,808$5,357
10
Maturity analysis under the lease agreements is as follows (in thousands):
Three months ending December 31, 2023$930 
Year ending December 31, 20243,792 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Thereafter5,915 
Total22,540 
Less: Present value discount(5,065)
Total operating lease liability17,475 
Less: Current portion(3,584)
Operating lease liabilities, non-current$13,891 
7. Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.75 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of ten years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
Purchase Commitments
The Company enters into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. The Company recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of September 30, 2023, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory during 2023 and 2024. The Company has paid deposits of $19.4 million and $21.6 million as of September 30, 2023 and December 31, 2022, respectively, for the various campaigns, which are recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
11
8. Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the nine-month periods ended September 30, 2023 and 2022, was comprised of the following (in thousands):
Nine Months Ended September 30,
20232022
Inventoriable costs$1,186 $1,307 
Selling, general and administrative25,269 19,293 
Research and development11,521 11,254 
Total share-based compensation expense$37,976 $31,854 
Information regarding the stock options activity, including with respect to grants to employees and directors as of September 30, 2023, and changes during the nine-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20224,785,972$26.27 5.8 years
Options granted 2023284,212
Options exercised 2023(645,977)
Options canceled or expired 2023(38,652)
Outstanding at September 30, 20234,385,555$27.96 
Vested and expected to vest at September 30, 20234,385,555$27.96 
Exercisable at September 30, 20233,605,710$23.37 
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity and changes during the nine-month period ended September 30, 2023 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20221,274,664$42.76 0.8 years
Time-based RSUs granted in 20231,090,927
Time-based RSUs vested in 2023(657,775)
Time-based RSUs cancelled in 2023(60,148)
Outstanding at September 30, 20231,647,668$48.90 
As of September 30, 2023, there was $61.3 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
12
9. Loss Per Share
The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2023 and 2022:
Three and Nine Months Ended
September 30,
20232022
Stock options4,385,5554,926,117
RSUs1,755,4601,495,711
13
Item 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed on March 1, 2023. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, as updated from time to time in our subsequent periodic and current reports filed with the SEC.
Overview
We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration, or FDA, for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). We initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). We initiated the commercial launch of these special population doses in August 2022. As used in this report, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression.

Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder, or MDD. Patient enrollment in Study 501 and Study 502, global Phase 3 clinical trials evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD, is ongoing. In addition, we initiated a third global Phase 3 trial, Study 505, also evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD. Study 505 is intended to serve as a potential additional registration trial in support of a supplemental New Drug Application, or sNDA, for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD, if needed. This is a common strategy employed in mood disorder development programs. We expect to announce topline results from Study 501 in the first quarter of 2024 and Study 502 in the second quarter of 2024 and, subject to the results of these studies, we expect to file an sNDA with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in the second half of 2024.

In the first quarter of 2020, as part of our lumateperone bipolar depression clinical program, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar I or bipolar II disorder. Following the positive results in our adjunctive study that was part of our bipolar depression clinical program, Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with bipolar I or bipolar II disorder and mixed features in patients with MDD. In March 2023, we announced positive topline results from Study 403 as lumateperone 42mg given once daily met the primary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (5.7 point reduction v. placebo; p<0.0001; Cohen’s d effect size (ES) of 0.64). Robust results were also seen in the individual patient population of MDD with mixed features (5.9 point reduction v. placebo; p<0.0001; ES= 0.67), and in the individual patient population of bipolar depression with mixed features (5.7 point reduction v. placebo; p<0.0001; ES= 0.64). Additionally, lumateperone 42mg met the key secondary endpoint in the study by demonstrating a statistically significant and clinically meaningful reduction in the clinician’s assessment of improvement in the overall severity on the Global Impression of Severity Scale (CGI-S) score compared to placebo at Week 6 in the combined patient population of MDD with mixed features and bipolar depression with mixed features (p<0.0001; ES= 0.59) and in the individual patient population of MDD with mixed features (p=0.0003; ES= 0.57), as well as the individual patient population of bipolar depression with mixed features p<0.0001; ES=0.61). We expect to discuss the results of Study 403 with the FDA in late 2023 or the first quarter of 2024.
14
We also have an ongoing study, Study 304, evaluating lumateperone for the prevention of relapse in patients with schizophrenia. The study is being conducted in five phases consisting of a screening phase; a 6-week, open-label run-in phase during which all patients will receive 42 mg of lumateperone per day; a 12-week, open-label stabilization phase during which all patients will receive 42 mg of lumateperone per day; a double-blind treatment phase, 26 weeks in duration, during which patients receive either 42 mg of lumateperone per day or placebo (1:1 ratio); and a 2-week safety follow-up phase. This study is being conducted in accordance with our post approval marketing commitment to the FDA in connection with the approval of CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics.
Within the lumateperone portfolio, we are also developing a long-acting injectable, or LAI, formulation to provide more treatment options to patients suffering from mental illness. We have conducted a Phase 1 single ascending dose study with our initial LAI formulation. This study evaluated the pharmacokinetics, safety and tolerability of this lumateperone LAI in patients with stable symptoms of schizophrenia and was safe and well-tolerated. We are also evaluating several additional formulations of the LAI with treatment durations of one month and longer. We have completed all non-clinical studies to support the initiation of a Phase 1 study with four additional formulations of our LAI. We expect to commence clinical conduct in this study in the first half of 2024. Given the encouraging tolerability data to date with oral lumateperone, we believe that an LAI option, in particular, may lend itself to being an important formulation choice for certain patients.
We are developing ITI-1284-ODT-SL for the treatment of agitation in patients with dementia, the treatment of dementia-related psychosis and the treatment of certain depressive disorders in the elderly. ITI-1284-ODT-SL is a deuterated form of lumateperone, a new molecular entity formulated as an oral disintegrating tablet for sublingual administration. ITI-1284-ODT-SL is formulated as an oral solid dosage form that dissolves almost instantly when placed under the tongue, allowing for ease of use in the elderly and may be particularly beneficial for patients who have difficulty swallowing conventional tablets. Phase 1 single and multiple ascending dose studies in healthy volunteers and healthy elderly volunteers (> than 65 years of age) evaluated the safety, tolerability and pharmacokinetics of ITI-1284-ODT-SL. In these studies, there were no reported serious adverse events in either age group. In the elderly cohort, reported adverse events were infrequent with the most common adverse event being transient dry mouth (mild). Based on these results, we have initiated Phase 2 programs evaluating ITI-1284-ODT-SL for the treatment of generalized anxiety disorder, psychosis in Alzheimer's disease and in patients with agitation in Alzheimer’s disease. The FDA has informed us that they do not believe the deuterated and undeuterated forms of lumateperone are identical. As a result, the non-clinical data from lumateperone may not be broadly applied to ITI-1284-ODT-SL, and we conducted additional toxicology studies. These studies have been completed and we expect to commence clinical conduct in our Phase 2 studies in the first half of 2024. We are continuing with Phase 1 studies with ITI-1284-ODT-SL, including drug-drug interaction studies.
We have another major program that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states, and our PDE1 inhibitors are designed to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of aberrant immune system activation in several CNS and non-CNS conditions with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include immune system regulation, neurodegenerative diseases, cancers and other non-CNS disorders. Lenrispodun (ITI-214) is our lead compound in this program. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for lenrispodun for Parkinson’s disease and conducted a Phase 1/2 clinical trial of lenrispodun in patients with Parkinson’s disease to evaluate safety and tolerability in this patient population, as well as motor and non-motor exploratory endpoints. In this study, lenrispodun was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. Our Phase 2 clinical trial of lenrispodun evaluating improvements in motor symptoms, changes in cognition, and inflammatory biomarkers in patients with Parkinson’s disease is ongoing. We expect to complete this study in the first half of 2025. We also have an active Investigational New Drug application to evaluate our newest candidate within the PDE 1 inhibitor program, ITI-1020, as a novel cancer immunotherapy. Our Phase 1 program with ITI-1020 in healthy volunteers is ongoing.
15
We also have a development program with our ITI-333 compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective, non-addictive treatments to manage pain. ITI-333 is a novel compound that uniquely combines activity as an antagonist at serotonin 5-HT2A receptors and a partial agonist at µ-opioid receptors. These combined actions support the potential utility of ITI-333 in the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns. We have conducted a Phase 1 single ascending dose study evaluating the safety, tolerability and pharmacokinetics of ITI-333 in healthy volunteers. In this study, ITI-333 achieved plasma exposures at or above those required for efficacy and was generally safe and well-tolerated. We have commenced a neuroimaging study to investigate brain occupancy for receptors that play a role in substance use disorder and also have applicability for pain. The results of this study will support the dose selection for future studies. We also have an ongoing multiple ascending dose study with ITI-333 in healthy volunteers that we expect to complete in 2024. We have received a grant from the National Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, that we expect will fund a significant portion of the early stage clinical development costs associated with this program.
We have assembled a management team with significant industry experience to lead the commercialization of our product and the discovery, development and potential commercialization of our product candidates. We complement our management team with a group of scientific and clinical advisors that includes recognized experts in the fields of schizophrenia, bipolar depression and other CNS disorders.
COVID-19
The COVID-19 pandemic has had widespread, rapidly evolving, and unpredictable impacts on global societies, economies, financial markets, and business practices. We continue to closely monitor the evolution and global impact of the COVID-19 pandemic, the identification of new variants of the COVID-19 virus and related developments, and our focus remains on promoting employee health and safety while continuing to advance the commercialization of our products and the research and development of our product candidates. Please refer to our Risk Factors in Part I, Item IA of our Annual Report on Form 10-K for further discussion of risks related to the COVID-19 pandemic.
Results of Operations
The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
Revenues
Net revenues from product sales consist of sales of CAPLYTA, which was approved by the FDA for the treatment of schizophrenia in adults in December 2019 and for the treatment of bipolar depression in adults in December 2021. In addition, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA for certain patients. During the three and nine-month periods ended September 30, 2023, net product sales increased to approximately $125.8 million and $330.7 million, respectively, from approximately $71.9 million and $161.7 million for the three and nine-month periods ended September 30, 2022, respectively.
Expenses
The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. The costs associated with the commercialization of CAPLYTA are substantial and will be incurred prior to our generating sufficient revenue to offset these costs. Costs for the clinical development of lumateperone-related projects, including for the treatment of MDD, consume and, together with our required post-marketing studies and other anticipated clinical development programs, will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials.
16
Our PDE, ITI-1284 and ITI-333 development programs are currently in clinical development. Our other programs are still in the pre-clinical stages and will require extensive funding not only to complete pre-clinical testing, but also to commence and complete clinical trials. Expenditures that we incur in connection with these programs will be subject to availability of funding in addition to the funding required for the advancement of lumateperone. Any failure or delay in the advancement of lumateperone could require us to re-allocate resources from our other programs to the advancement of lumateperone, which could have a material adverse impact on the advancement of these other programs and on our results of operations.
Our operating expenses are comprised of (i) costs of product sales; (ii) selling expenses; (iii) general and administrative expenses; and (iv) research and development expenses.
Costs of product sales are comprised of:
•royalty payments on product sales;
•direct costs of formulating, manufacturing and packaging drug product; and
•overhead costs consisting of labor, share-based compensation, shipping, outside inventory manufacturing and other miscellaneous operating costs.
Selling expenses are incurred in three major categories:
•salaries and related benefit costs of a dedicated sales force;
•marketing and promotion expenses; and
•sales operation costs.
General and administrative expenses are incurred in three major categories:
•salaries and related benefit costs;
•patent, legal, and professional costs; and
•office and facilities overhead.
Research and development costs are comprised of:
•fees paid to external parties that provide us with contract services, such as pre-clinical testing, manufacturing and related testing, clinical trial activities and license milestone payments; and
•internal recurring costs, such as costs relating to labor and fringe benefits, materials, supplies, facilities and maintenance.

Product sold through September 30, 2023 consisted of active pharmaceutical ingredient (API) and drug product that was previously charged to research and development expenses prior to FDA approval of CAPLYTA and other direct, indirect, and overhead costs required to make final product for sale. Because the Company’s policy does not allow for the capitalization of pre-approval product, the cost of drug product sold is lower than it would have been and has a positive impact on our cost of product sales for the three and nine-month periods ended September 30, 2023 and 2022. We expect to continue to have this favorable impact on cost of product sales and related product gross margins until the cost of our sales of CAPLYTA include drug product that is manufactured entirely after the FDA approval. We expect that this will be the case for the near-term and, as a result, our cost of product sales is less than we anticipate it will be in future periods. In addition, as our net product sales increase in the future and, we exceed certain sales thresholds, the applicable royalty rate for payments we make under our License Agreement with Bristol Myers Squibb (BMS) will increase, which we anticipate will result in an increase to cost of product sales.
17
We expect that research and development expenses will increase moderately as we proceed with our clinical trials including, increased manufacturing of drug product for clinical trials and pre-clinical development activities. We also expect that our selling, general and administrative costs will increase from prior periods primarily due to costs associated with promotional activities to support the commercial sales of CAPLYTA as well as costs associated with building and maintaining infrastructure, which will include hiring additional personnel and increasing technological capabilities. We granted significant share-based awards in 2023 and 2022. We expect to continue to grant share-based awards in the future. We expect that our growing employee base will increase our share-based compensation expense in future periods. In addition, inflation has and may continue to affect us by increasing clinical trial and other operational costs. To date, inflation has not had a material impact on our business, but if the global inflationary trends continue, we expect appreciable increases in clinical trial, selling, labor, and other operating costs.
The following table sets forth our revenues, operating expenses, interest income and income tax expense for the three and nine-month periods ended September 30, 2023 and 2022 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
(Unaudited) (Unaudited)
Revenues
Product sales, net$125,810 $71,870 $330,669 $161,699 
Grant revenue363 — 1,602 746 
Total revenues126,173 71,870 332,271 162,445 
Expenses
Cost of product sales9,129 5,850 23,043 13,655 
Selling, general and administrative105,207 88,375 305,144 264,151 
Research and development41,550 33,274 129,368 100,853 
Total operating expenses155,886 127,499 457,555 378,659 
Loss from operations(29,713)(55,629)(125,284)(216,214)
Interest income5,498 2,122 14,377 3,990 
Income tax expense(43)(1)(188)(6)
Net loss$(24,258)$(53,508)$(111,095)$(212,230)
Comparison of Three and Nine-Month Periods Ended September 30, 2023 and September 30, 2022
Product Sales, Net
Net product sales were $125.8 million and $330.7 million for the three and nine-month periods ended September 30, 2023, respectively, compared to $71.9 million and $161.7 million for the three and nine-month periods ended September 30, 2022, respectively. Net product sales for the periods presented are comprised of sales of CAPLYTA for the treatment of schizophrenia and bipolar depression.
Cost of Product Sales
Cost of product sales was $9.1 million and $23.0 million for the three and nine-month periods ended September 30, 2023, respectively, compared to $5.9 million and $13.7 million for the three and nine-month periods ended September 30, 2022, respectively. Cost of product sales consisted primarily of product royalty fees and direct and overhead costs. Drug product costs, including certain direct, indirect, and overhead costs, for product sales from commercial launch through September 30, 2023 were previously charged to research and development expenses prior to FDA approval in December 2019 and are not a component of cost of product sales. This minimal cost drug product had a favorable impact on our cost of product sales and related product gross margins for the three and nine-month periods ended September 30, 2023 and 2022.
18
We expect product sales in future quarters will continue to be impacted by lower cost of product sales that excludes the cost of the drug product that was incurred prior to FDA approval until our sales of CAPLYTA include drug product that is entirely manufactured after the FDA approval. We expect that this will continue to be the case for the near-term and, as a result, our cost of product sales will be less than we anticipate it will be in future periods. We expect cost of product sales will increase in future quarters as minimum sales thresholds are met, resulting in royalty payment increases under the BMS License Agreement.
Selling, General and Administrative Expenses
Selling, general and administrative costs for the three-month period ended September 30, 2023 were $105.2 million as compared to $88.4 million in the three-month period ended September 30, 2022, which represents an increase of 19%.
Selling costs were $80.9 million for the three-month period ended September 30, 2023 as compared to selling costs of $68.1 million in the same period in 2022, which represents an increase of 19%. This increase is primarily due to increases of marketing and advertising expenses of $6.8 million, sales related labor costs of $5.0 million primarily due to the increase in our sales force, and travel and other sales related expenses of $1.0 million. Salaries, bonuses and related benefit costs for our sales and marketing functions for the three-month periods ended September 30, 2023 and 2022 constituted 35% and 34%, respectively, of our selling costs.
General and administrative expenses were $24.3 million in the three-month period ended September 30, 2023 as compared to $20.3 million for the same period in 2022, an increase of 20%. This increase is due to increases in share-based compensation of $2.5 million, professional and other administrative expenses of $1.0 million, and the remainder of the increase relates to information technology related costs of $0.5 million. Salaries, bonuses and related benefit costs for our general and administrative functions for the three-month periods ended September 30, 2023 and 2022 constituted 18% and 23%, respectively, of our general and administrative costs.
Selling, general and administrative costs for the nine-month period ended September 30, 2023 were $305.1 million as compared to $264.2 million in the nine-month period ended September 30, 2022, which represents an increase of 16%.
Selling costs were $233.5 million for the nine-month period ended September 30, 2023 as compared to $205.4 million in the same period in 2022, or an increase of 14%. This increase is primarily due to increases in commercialization costs of $14.5 million, sales related labor costs of $11.1 million primarily due to the increase in our sales force and $2.5 million in travel and other sales related expenses. Salaries, bonuses and related benefit costs for our sales and marketing functions for the nine-month periods ended September 30, 2023 and 2022 constituted approximately 35% of our selling costs.
General and administrative expenses for the nine-months ended September 30, 2023 were $71.6 million as compared to $58.7 million for the same period in 2022, an increase of 22%. This increase is due to increases in stock compensation expense of $6.0 million, labor related expense of $2.0 million, and the remainder for insurance, lease expense, and other administrative expenses. Salaries, bonuses and related benefit costs for our general and administrative functions for the nine-month periods ended September 30, 2023 and 2022 constituted approximately 22% and 23%, respectively, of our general and administrative costs.
We expect selling, general and administrative costs to increase moderately in 2023 as compared to 2022 due to our sales force expansion and increased marketing, promotional and advertising costs.
19
Research and Development Expenses
The following tables set forth our research and development expenses for the three and nine-month periods ended September 30, 2023 and 2022 (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
External service costs$29,123 $22,654 $94,579 $69,801 
Internal and other costs12,427 10,620 34,789 31,052 
Total research and development expenses$41,550 $33,274 $129,368 $100,853 
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Lumateperone costs$23,149 $16,877 $78,510 $56,487 
Non-lumateperone costs9,614 9,017 27,670 23,281 
Overhead and other costs8,787 7,380 23,188 21,085 
Total research and development expenses$41,550 $33,274 $129,368 $100,853 
Research and development expenses increased to $41.6 million for the three-month period ended September 30, 2023 as compared to $33.3 million for the three-month period ended September 30, 2022, representing an increase of $8.3 million, or 25%. This increase is due primarily to an increase of $6.3 million for lumateperone project costs, an increase of $0.6 million for non-lumateperone projects, and an increase of $1.4 million for overhead and other costs. External service costs increased by $6.5 million for the period due to the increased lumateperone and non-lumateperone clinical trials as well as other project costs. Internal and other costs increased by $1.8 million for the period due primarily to labor related costs and share-based compensation.
Research and development expenses increased to $129.4 million for the nine-month period ended September 30, 2023 as compared to $100.9 million for the nine-month period ended September 30, 2022, representing an increase of $28.5 million, or 28%. This increase is due primarily to increases of $22.0 million for lumateperone project costs, $4.4 million for non-lumateperone projects, and $2.1 million for overhead and other costs. External service costs increased by $24.8 million for the period due to the increased lumateperone and non-lumateperone project costs. Internal and other costs increased by $3.7 million for the period due primarily to labor related costs and share-based compensation.
The successful development of our product candidates and the approval process requires substantial time, effort and financial resources, and is uncertain and subject to a number of risks. We cannot be certain that any of our product candidates will prove to be safe and effective, will meet all of the applicable regulatory requirements needed to receive and maintain marketing approval, or will be granted marketing approval on a timely basis, if at all. Data from non-clinical studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent regulatory approval or could result in label warnings related to or recalls of approved products. We, the FDA, or other regulatory authorities may suspend clinical trials at any time if we or they believe that the subjects participating in such trials are being exposed to unacceptable risks or if such regulatory agencies find deficiencies in the conduct of the trials or other problems with our product candidates. Other risks associated with our product candidates are described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated by the section titled “Risk Factors” in this Quarterly Report on Form 10-Q and from time to time in our other periodic and current reports filed with the SEC.
Liquidity and Capital Resources
Since our inception, we have incurred significant operating and cash losses from our operations. We have primarily funded our operations to date through proceeds from public and private offerings of our common stock and other securities, and to a far lesser extent, through proceeds from grants from government agencies and foundations. In addition, we began to generate net product revenue in the first quarter of 2020 in conjunction with the commercial launch of CAPLYTA.
20
As of September 30, 2023, our cash and cash equivalents, available-for-sale investment securities, and restricted cash totaled $494.8 million. We invest cash in excess of our immediate requirements with regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances and investments with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such balances.
During the nine months ended September 30, 2023, we used $122.1 million of net cash in operating activities, a decrease of $108.9 million as compared to the nine months ended September 30, 2022. The decrease in net cash used in operations was primarily due to higher sales offset partially by increases in operating expenses. The primary uses of cash were for selling and marketing costs in connection with our commercialization of CAPLYTA, conducting clinical trials and non-clinical testing, funding recurring operating expenses, and product manufacturing.
Based on our current operating plans, we expect that our existing cash, cash equivalents, marketable securities, and product sales will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing date of this quarterly report. During that time, we expect that our expenses will increase, primarily due to the continued commercialization of CAPLYTA for the treatment of schizophrenia and bipolar depression; the development of lumateperone in our late-stage clinical programs; the development of our other product candidates and programs, including PDE, ITI-1284, and ITI-333; and infrastructure expansion and general operations.
We seek to balance the level of cash, cash equivalents and investments on hand with our projected needs and to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. Subject to our ability to generate significant revenues from operations, we may need to satisfy our future cash needs through public or private sales of our equity securities, sales of debt securities, incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of our product candidates and technology and, to a lesser extent, grant funding.
We cannot be sure that future funding will be available to us when we need it on terms that are acceptable to us, or at all. We sell securities and incur debt when the terms of such transactions are deemed favorable to us and as necessary to fund our current and projected cash needs. The amount of funding we raise through sales of our common stock or other securities depends on many factors, including, but not limited to, the magnitude of sales of CAPLYTA, the status and progress of our product development programs, projected cash needs, availability of funding from other sources, our stock price and the status of the capital markets. Due to the volatile nature of the financial markets, equity and debt financing may be difficult to obtain.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
If adequate funds are not available to us on a timely basis, we may be required to: (1) delay, limit, reduce or terminate non-clinical studies, clinical trials or other clinical development activities for one or more of our product candidates, including our lead product candidate lumateperone and our other product candidates; (2) delay, limit, reduce or terminate our discovery research or non-clinical development activities; (3) enter into licenses or other arrangements with third parties on terms that may be unfavorable to us or sell, license or relinquish rights to develop or commercialize our product candidates, technologies or intellectual property at an earlier stage of development and on less favorable terms than we would otherwise agree; or (4) limit or reduce commercialization efforts related to CAPLYTA.
21
Our cash, cash equivalents, and investments are maintained in checking accounts, money market accounts, money market mutual funds, U.S. government agency securities, certificates of deposit, commercial paper, corporate notes and corporate bonds at major financial institutions. Since early 2022, interest rates have risen which is increasing our interest income. During 2023, there was a decrease in unrealized loss primarily due to maturities of lower yielding investments. Due to the short-term nature of these investments and our intention to hold these investments to maturity, we do not expect to recognize these losses. Even with the rise or further potential rise in interest rates, we do not expect interest income to be a significant source of funding. In addition, our investment portfolio historically has not been adversely impacted by problems in the credit markets, but there can be no assurance that our investment portfolio will not be adversely affected in the future.
Our cash requirements in the short and long term consist primarily of operational and manufacturing expenditures, a portion of which contain contractual or other obligations. We plan to fund our cash requirements with our current financial resources together with our anticipated receipts from product sales. We manage future cash requirements relative to our long-term business plans. Our primary uses of cash relate to marketing and manufacturing our products, paying employees and consultants, administering clinical trials, and providing technology and facility infrastructure to support our operations.
We have three kinds of long-term contractual commitments - operating leases, licensing and royalty commitments, and purchase obligations. Our operating lease for approximately 32,000 square feet of useable laboratory and office space, as amended, had an original term of 14.3 years ending in May 2029.
We entered into an exclusive license with BMS for which we are obligated to make tiered single-digit percentage royalty payments on sales of licensed products. The amount of future royalty obligations are dependent on future net product sales of the licensed product. The Company may also be obligated to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million.
In addition, we have entered into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. We recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which we anticipate payments being made within the years 2025 through 2029. We also have entered into short-term agreements with various vendors and suppliers of goods and services in the normal course of operations through purchase orders. Such short-term agreements are generally outstanding for periods less than a year and are settled by cash payments upon delivery of goods and services. The nature of the work being conducted under these agreements is such that, in most cases, the services may be stopped on short notice without penalty. In such event, we would not be liable for the full amount of the agreement. We also have entered into clinical trial agreements which may span over multiple years.
Critical Accounting Policies and Estimates
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to our critical accounting policies during the nine-month period ended September 30, 2023.
The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented. Judgments must also be made about the disclosure of contingent liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management makes estimates and exercises judgment in research and development, including clinical trial accruals. Actual results may differ from those estimates and under different assumptions or conditions.
22
Recently Issued Accounting Pronouncements
We review new accounting standards to determine the expected financial impact, if any, that the adoption of each such standard will have. Based on our assessment, all new accounting pronouncements were determined to be either not applicable or are expected to have minimal impact on our consolidated financial statements or related disclosures.
Certain Factors That May Affect Future Results of Operations
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the accuracy of our estimates regarding expenses, revenues, uses of cash, cash equivalents and investment securities, capital requirements and the need for additional financing; our expectations regarding our commercialization of CAPLYTA; the duration and severity of the COVID-19 pandemic and its continued impact on our business; the supply and availability of and demand for our product; the initiation, cost, timing, progress and results of our development activities, pre-clinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval, or submit an application for regulatory approval, of lumateperone and our other existing product candidates, any product candidates that we may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize lumateperone and our other current and future product candidates; the election by any collaborator to pursue research, development and commercialization activities; our ability to obtain future reimbursement and/or milestone payments from our collaborators; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to successfully commercialize lumateperone and our other product candidates; the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials; our ability to obtain additional financing; our use of the proceeds from our securities offerings; our exposure to investment risk, interest rate risk, inflation risk, capital market risk, and geopolitical instability; and our ability to attract and retain key scientific, management, or sales and marketing personnel.
Words such as “may,” “anticipate,” “estimate,” “expect,” “may,” “project,” “intend,” “plan,” “believe,” “potential,” “predict,” “project,” “likely,” “will,” “would,” “could,” “should,” “continue” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in commercializing CAPLYTA; the COVID-19 pandemic may negatively impact our commercial plans and sales for CAPLYTA; the COVID-19 pandemic may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, our clinical trials; whether CAPLYTA receives adequate reimbursement from third-party payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indications; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia and bipolar depression following commercial launch of the product may be different than observed in clinical trials, and may vary among patients; any other impacts on our business as a result of or related to the COVID-19 pandemic; challenges associated with supply and manufacturing activities, which in each case could limit our sales and the availability of our product; impacts on our business, including on the commercialization of CAPLYTA and our clinical trials, as a result of the conflicts in Ukraine and Israel; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA following commercial launch for the treatment of schizophrenia or bipolar depression or in ongoing or future trials and other development activities; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development, commercialization, manufacturing or supply of our product and product candidates; risks related to increased interest rates, high rates of inflation, global supply chain disruptions, and geopolitical instability on our business; and the other risk factors detailed under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated under the heading “Risk Factors” from time to time in our subsequent periodic and current reports filed with the SEC.
23
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
Item 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity. As of September 30, 2023, we had cash, cash equivalents, marketable securities and restricted cash of $494.8 million consisting of cash deposited in a highly rated financial institution in the United States and in a short-term U.S. Treasury money market fund, as well as high-grade corporate bonds and commercial paper. The primary objective of our investment activities is to preserve our capital for the purpose of funding operations and we do not enter into investments for trading or speculative purposes. We believe that we do not have material exposure to high-risk investments such as mortgage-backed securities, auction rate securities or other special investment vehicles within our money-market fund investments. We believe that we do not have any material exposure to changes in fair value as a result of changes in interest rates. Since early 2022, interest rates have risen which is increasing our interest income. During 2023, there was a decrease in unrealized loss primarily due to maturities of lower yielding investments. This gain resulted in a lower net unrealized loss balance of $1.3 million as of September 30, 2023.
Inflation Risk. Inflation generally may affect us by increasing our cost of labor, clinical trial costs, and costs of other outsourced activities. To date, inflation has not had a material impact on our business, but if the global inflationary trends continue, we expect appreciable increases in clinical trial, selling, labor, and other operating costs. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases of our product or cash flows from other sources. Our inability or failure to do so could adversely affect our business, financial condition and results of operations.
Capital Market Risk. Although we receive product revenues from commercial sales of CAPLYTA, we continue to assess the need for additional funding through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price.
Item 4.    CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
(b) Changes in Internal Controls. There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the three-month period ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
24
PART II: OTHER INFORMATION
Item 1.    LEGAL PROCEEDINGS

On July 8, 2022, a purported shareholder derivative complaint was filed in the Supreme Court for the State of New York against the directors serving on the Company’s board of directors and the Company as a nominal defendant alleging breach of fiduciary duty and unjust enrichment alleging that compensation awarded to the director defendants for service on the board of directors was excessive. On March 6, 2023, the parties filed a stipulation of settlement (the “Stipulation”). The Stipulation does not require any damages payments or disgorgement by defendants or the Company. The Stipulation provides that, going forward, the board of directors will amend its compensation policies for non-employee directors, including, inter alia, by capping annual equity compensation at the 75th percentile of the annual equity grants for a peer group of companies. Subject to the terms and conditions of the Stipulation and final approval of the Court, the Company and/or its insurance carriers have agreed to pay up to $375,000 in attorneys’ fees to plaintiff’s counsel. On April 12, 2023, the court granted preliminary approval of the settlement and on July 17, 2023 the court approved the Stipulation.
Item 1A. RISK FACTORS
There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 1, 2023.
Item 2.    UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES
Unregistered Sales of Equity Securities
Not applicable.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the quarter ended September 30, 2023.
Item 3.    DEFAULTS UPON SENIOR SECURITIES
Not applicable.
Item 4.    MINE SAFETY DISCLOSURES
Not applicable.
Item 5.    OTHER INFORMATION

During the fiscal quarter ended September 30, 2023, the following executive officer modified his "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act):

•On August 11, 2023, Michael I. Halstead, Executive Vice President, General Counsel and Secretary, modified his Rule 10b5-1 Trading Plan, originally adopted on March 15, 2023 and modified on May 8, 2023, to change the start date of the plan to November 13, 2023, and increase the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 137,872 shares of our common stock until March 28, 2024.

There were no "non-Rule 10b5-1 trading arrangements" (as defined in Item 408 of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended September 30, 2023 by our directors and executive officers.
25
Item 6.    EXHIBITS
Exhibit
Number
Exhibit Description
Filed
Herewith
Incorporated by
Reference herein
from Form
or Schedule
Filing Date
SEC File/
Reg. Number
31.1X
31.2X
32X
101
The following materials from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022 (audited), (ii) Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2023 and 2022, (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2023 and 2022, (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2023 and 2022, (v) Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2023 and 2022, and (vi) Notes to Condensed Consolidated Financial Statements (unaudited).
X
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X


26
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INTRA-CELLULAR THERAPIES, INC.
Date: November 2, 2023
By:/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
Date: November 2, 2023
By:/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
27
 EX-31.1 2 itci-20230930xex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS UNDER SECTION 302
I, Sharon Mates, Ph.D., certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 2, 2023
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
(principal executive officer)

 EX-31.2 3 itci-20230930xex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS UNDER SECTION 302
I, Lawrence J. Hineline, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 2, 2023
/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
(principal financial officer)

 EX-32 4 itci-20230930xex32.htm EX-32 Document

Exhibit 32
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report for the quarter ended September 30, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 2, 2023
/s/ Sharon Mates, Ph.D.
Sharon Mates, Ph.D.
Chairman, President and Chief Executive Officer
(principal executive officer)
Dated: November 2, 2023
/s/ Lawrence J. Hineline
Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer
(principal financial officer)

EX-101.SCH 5 itci-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investment Securities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Right of Use Assets and Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Loss Per Share - (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Investment Securities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 itci-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 itci-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 itci-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Range [Domain] Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Outstanding at beginning of year, Number of Shares (in shares) Outstanding at end of year, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Investment Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Corporate Notes/Bonds Corporate Debt Securities [Member] Purchases of investments Payments to Acquire Investments Insider Trading Policies and Procedures [Line Items] Exercisable at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Proceeds of public offering, net Proceeds from Issuance of Common Stock Right of Use Assets and Lease Liabilities Right Of Use Assets And Lease Liabilities [Text Block] Right of use assets and lease liabilities. Exercise of stock options and issuances of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Outstanding at beginning of period, Number of Shares (in shares) Outstanding at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Accrued employee benefits Accrued Employee Benefits, Current Trading Symbol Trading Symbol U.S. Government Agency Securities US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Payment of milestone amount Possible Milestone Payments Remaining Payment of milestone amount. Purchase Commitment Purchase Commitment [Member] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Unrealized (Losses) Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Options exercised, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Executive Category: Executive Category [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Certificates of Deposit Certificates of Deposit [Member] Investment Type [Axis] Investment Type [Axis] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Selling, general and administrative Selling, General and Administrative Expenses [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities, non-current Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Thereafter Lessee Operating Lease Liability Payments Due after Year Four Lessee operating lease liability payments due after Year four. RSUs Restricted Stock Units (RSUs) [Member] Summary of Information Regarding RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Purchase Commitment, Excluding Long-Term Commitment [Axis] Schedule Of Maturity Analysis Under Lease Agreements Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] FDIC Certificates of Deposit FDIC Certificates Of Deposit [Member] FDIC certificates of deposit. Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Unrealized gain (loss) on investment securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development Research and Development Expense [Member] Cash flows provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Schedule of Quantitative Information About Operating Leases Schedule of Quantitative Information About Operating Leases [Table Text Block] Schedule of Quantitative Information About Operating Leases Number of anti-dilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Time based RSU's granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Unrecognized compensation costs related to unvested RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Outstanding at end of period, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Right of use assets under operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Less: Present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating lease liabilities Less: Current portion Operating Lease, Liability, Current Entity Shell Company Entity Shell Company Year ending December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] Year ending December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Weighted average number of common shares: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Aggregate fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Time based RSU's vested, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Security Exchange Name Security Exchange Name Assets measured using quoted prices Available-for-sale investment securities Assets, Fair Value Disclosure Percentage of fair value instruments Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments Accumulated comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Carrying value of cash held in commercial paper, government securities US Government Agencies Securities, at Carrying Value Stock options Share-Based Payment Arrangement, Option [Member] Employee Stock Option [Member] Maximum Maximum [Member] Customer Three Customer Three [Member] Customer three. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Short-term lease cost Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Accrued and other current liabilities Accrued Liabilities and Other Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted- Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Customer Concentration Risk Customer Concentration Risk [Member] Customer Two Customer Two [Member] Customer two. Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Common shares issued (in shares) Stock Issued During Period, Shares, New Issues Operating expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventory Total inventories Inventory, Net Total lease cost Lease, Cost Range [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Product sales, net Product Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows used in operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Customer One Customer One [Member] Customer one. Certificates of deposits Certificates of Deposit, at Carrying Value PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Asset Class [Domain] Asset Class [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Company made an upfront payment Collaborative Agreement Upfront Payments Collaborative Agreement Upfront Payments Name of Property [Domain] Name of Property [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total operating lease liability Operating Lease, Liability Total liabilities Liabilities Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Aggregate related fair value of investments with unrealized losses Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Net loss per common share: Earnings Per Share [Abstract] Other information Other Information [Abstract] Other information. Common stock, $0.0001 par value: 175,000,000 shares authorized at September 30, 2023 and December 31, 2022; 96,225,617 and 94,829,794 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Continuous unrealized losses, value remaining Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Selling, general and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Stock issued for services Issuance of Stock and Warrants for Services or Claims All Individuals All Individuals [Member] Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Concentration risk (as a percent) Concentration Risk, Percentage Time based RSU's granted, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted cash Restricted Cash, Current Significant Accounting Policies Significant Accounting Policies [Policy Text Block] Significant accounting policies. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Investment securities, available-for-sale Debt Securities, Available-for-Sale, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Accrued employee benefits Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Commercial Paper Commercial Paper [Member] Obliged to make milestone payments Collaborative Arrangement Amount Payable Collaborative arrangement amount payable. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Revenue Recognition, Multiple-deliverable Arrangements [Table] Revenue Recognition, Multiple-deliverable Arrangements [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Year ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Year ending December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Total share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Options granted, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Investment securities, available for sale, noncurrent Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Term of long term lease Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Cash paid Cash Other comprehensive gain (loss) Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Liabilities measured using quoted prices Liabilities, Fair Value Disclosure Operating lease liabilities, net Increase (Decrease) in Operating Lease Liability Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Amortization of premiums and accretion of discounts on investment securities, net Accretion (Amortization) of Discounts and Premiums, Investments Total liabilities and stockholders’ equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (in dollars per share) Earnings Per Share, Basic Right of use assets, net Operating Lease, Right-of-Use Asset Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Three months ending December 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment, Excluding Long-Term Commitment [Domain] Michael I. Halstead [Member] Michael I. Halstead Stock issued for services Stock Issued During Period, Value, Issued for Services Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Cost of product sales Cost Of Product Sales Cost of product sales. Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Fair Value Debt Securities, Available-for-Sale Inventoriable costs Inventoriable Costs [Member] InventoriableCostsMember. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Accrued customer programs Increase Decrease In Accrued Customer Programs Increase decrease in accrued customer programs. Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Commercial paper value listed as cash equivalent Commercial Paper, at Carrying Value NEW YORK NEW YORK Investment Securities Investment [Text Block] Compensation Amount Outstanding Recovery Compensation Amount Other comprehensive gain (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Time based RSU's cancelled, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Proceeds from exercise of stock options Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Time based RSU's cancelled, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Exercise of stock options and issuances of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key License expiration period Collaborative Arrangement License Expiration Term Collaborative arrangement license expiration description. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Restricted stock outstanding, Weighted-Average Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Time Based Restricted Stock Units Time Based Restricted Stock Units R S U [Member] Time based restricted stock units. Fair Value Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Common shares issued Stock Issued During Period, Value, New Issues Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Total revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Money Market Funds Money Market Funds [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Stock issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Royalty payment, percentage (as a percent) Royalty Payment Percentage Royalty Payment Percentage Diluted (in share) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Carrying value of cash held in money market funds Money Market Funds, at Carrying Value Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Vehicle Lease Vehicles [Member] Lease cost Lease, Cost [Abstract] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Cover [Abstract] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Grant revenue Grant [Member] Time based RSU's vested, Weighted-Average Grant Date Fair Value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Options canceled or expired, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Total Lessee, Operating Lease, Liability, to be Paid Total operating expenses Operating Expenses Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Three Major Wholesalers Three Major Wholesalers [Member] Three Major Wholesalers Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Bristol-Myers Squibb Company Bristol Myers Squibb Company [Member] Bristol Myers Squibb company. Cash and Cash Equivalents Cash and Cash Equivalents [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Vested or expected to vest at end of period, Number of Shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Accrued customer programs Accrued Customer Programs Current Accrued customer programs current. Guarantor obligations, value Guarantor Obligations, Current Carrying Value Name of Property [Axis] Name of Property [Axis] EX-101.PRE 9 itci-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2023
Oct. 31, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-36274  
Entity Registrant Name INTRA-CELLULAR THERAPIES, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 36-4742850  
Entity Address, Address Line One 430 East 29th Street  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10016  
City Area Code 646  
Local Phone Number 440-9333  
Title of 12(b) Security Common Stock  
Trading Symbol ITCI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   96,238,126
Entity Central Index Key 0001567514  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 99,402 $ 148,615
Investment securities, available-for-sale 393,619 443,290
Restricted cash 1,750 1,750
Accounts receivable, net 102,670 75,189
Inventory 42,986 23,920
Prepaid expenses and other current assets 61,998 45,193
Total current assets 702,425 737,957
Property and equipment, net 1,789 1,913
Right of use assets, net 13,364 14,824
Other assets 86 86
Total assets 717,664 754,780
Current liabilities:    
Accounts payable 10,613 10,395
Accrued and other current liabilities 27,829 19,657
Accrued customer programs 35,618 25,621
Accrued employee benefits 25,448 22,996
Operating lease liabilities 3,584 4,567
Total current liabilities 103,092 83,236
Operating lease liabilities, non-current 13,891 15,474
Total liabilities 116,983 98,710
Stockholders’ equity:    
Common stock, $0.0001 par value: 175,000,000 shares authorized at September 30, 2023 and December 31, 2022; 96,225,617 and 94,829,794 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively 10 9
Additional paid-in capital 2,190,587 2,137,737
Accumulated deficit (1,588,581) (1,477,486)
Accumulated comprehensive loss (1,335) (4,190)
Total stockholders’ equity 600,681 656,070
Total liabilities and stockholders’ equity $ 717,664 $ 754,780
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 175,000,000 175,000,000
Common stock, shares issued (in shares) 96,225,617 94,829,794
Common stock, shares outstanding (in shares) 96,225,617 94,829,794
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenues, net $ 126,173 $ 71,870 $ 332,271 $ 162,445
Operating expenses:        
Cost of product sales 9,129 5,850 23,043 13,655
Selling, general and administrative 105,207 88,375 305,144 264,151
Research and development 41,550 33,274 129,368 100,853
Total operating expenses 155,886 127,499 457,555 378,659
Loss from operations (29,713) (55,629) (125,284) (216,214)
Interest income 5,498 2,122 14,377 3,990
Loss before provision for income taxes (24,215) (53,507) (110,907) (212,224)
Income tax expense (43) (1) (188) (6)
Net loss $ (24,258) $ (53,508) $ (111,095) $ (212,230)
Net loss per common share:        
Basic (in dollars per share) $ (0.25) $ (0.57) $ (1.16) $ (2.26)
Diluted (in dollars per share) $ (0.25) $ (0.57) $ (1.16) $ (2.26)
Weighted average number of common shares:        
Basic (in shares) 96,143,083 94,516,794 95,745,641 93,809,124
Diluted (in share) 96,143,083 94,516,794 95,745,641 93,809,124
Product sales, net        
Total revenues, net $ 125,810 $ 71,870 $ 330,669 $ 161,699
Grant revenue        
Total revenues, net $ 363 $ 0 $ 1,602 $ 746
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (24,258) $ (53,508) $ (111,095) $ (212,230)
Other comprehensive gain (loss):        
Unrealized gain (loss) on investment securities 933 (694) 2,855 (5,132)
Comprehensive loss $ (23,325) $ (54,202) $ (108,240) $ (217,362)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2021   81,886,965      
Beginning balance at Dec. 31, 2021 $ 417,890 $ 8 $ 1,639,476 $ (1,221,230) $ (364)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common shares issued (in shares)   10,952,381      
Common shares issued 433,725 $ 1 433,724    
Exercise of stock options and issuances of restricted stock (in shares)   1,180,696      
Exercise of stock options and issuances of restricted stock 8,089   8,089    
Stock issued for services (in shares)   383      
Stock issued for services 24   24    
Share-based compensation 8,105   8,105    
Net loss (72,119)     (72,119)  
Other comprehensive gain (loss) (2,964)       (2,964)
Ending balance at Mar. 31, 2022 792,750 $ 9 2,089,418 (1,293,349) (3,328)
Ending balance (in shares) at Mar. 31, 2022   94,020,425      
Beginning balance (in shares) at Dec. 31, 2021   81,886,965      
Beginning balance at Dec. 31, 2021 417,890 $ 8 1,639,476 (1,221,230) (364)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (212,230)        
Ending balance at Sep. 30, 2022 685,422 $ 9 2,124,369 (1,433,460) (5,496)
Ending balance (in shares) at Sep. 30, 2022   94,701,662      
Beginning balance (in shares) at Mar. 31, 2022   94,020,425      
Beginning balance at Mar. 31, 2022 792,750 $ 9 2,089,418 (1,293,349) (3,328)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   346,411      
Exercise of stock options and issuances of restricted stock 5,504   5,504    
Stock issued for services (in shares)   397      
Stock issued for services 22   22    
Share-based compensation 11,998   11,998    
Net loss (86,603)     (86,603)  
Other comprehensive gain (loss) (1,474)       (1,474)
Ending balance at Jun. 30, 2022 722,197 $ 9 2,106,942 (1,379,952) (4,802)
Ending balance (in shares) at Jun. 30, 2022   94,367,233      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   333,954      
Exercise of stock options and issuances of restricted stock 5,654   5,654    
Stock issued for services (in shares)   475      
Stock issued for services 22   22    
Share-based compensation 11,751   11,751    
Net loss (53,508)     (53,508)  
Other comprehensive gain (loss) (694)       (694)
Ending balance at Sep. 30, 2022 685,422 $ 9 2,124,369 (1,433,460) (5,496)
Ending balance (in shares) at Sep. 30, 2022   94,701,662      
Beginning balance (in shares) at Dec. 31, 2022   94,829,794      
Beginning balance at Dec. 31, 2022 656,070 $ 9 2,137,737 (1,477,486) (4,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   849,827      
Exercise of stock options and issuances of restricted stock 3,640 $ 1 3,639    
Stock issued for services (in shares)   408      
Stock issued for services 22   22    
Share-based compensation 10,439   10,439    
Net loss (44,053)     (44,053)  
Other comprehensive gain (loss) 1,492       1,492
Ending balance at Mar. 31, 2023 627,610 $ 10 2,151,837 (1,521,539) (2,698)
Ending balance (in shares) at Mar. 31, 2023   95,680,029      
Beginning balance (in shares) at Dec. 31, 2022   94,829,794      
Beginning balance at Dec. 31, 2022 656,070 $ 9 2,137,737 (1,477,486) (4,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (111,095)        
Ending balance at Sep. 30, 2023 600,681 $ 10 2,190,587 (1,588,581) (1,335)
Ending balance (in shares) at Sep. 30, 2023   96,225,617      
Beginning balance (in shares) at Mar. 31, 2023   95,680,029      
Beginning balance at Mar. 31, 2023 627,610 $ 10 2,151,837 (1,521,539) (2,698)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   402,994      
Exercise of stock options and issuances of restricted stock 8,585   8,585    
Stock issued for services (in shares)   364      
Stock issued for services 23   23    
Share-based compensation 13,226   13,226    
Net loss (42,784)     (42,784)  
Other comprehensive gain (loss) 430       430
Ending balance at Jun. 30, 2023 607,090 $ 10 2,173,671 (1,564,323) (2,268)
Ending balance (in shares) at Jun. 30, 2023   96,083,387      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and issuances of restricted stock (in shares)   141,780      
Exercise of stock options and issuances of restricted stock 2,581   2,581    
Stock issued for services (in shares)   450      
Stock issued for services 24   24    
Share-based compensation 14,311   14,311    
Net loss (24,258)     (24,258)  
Other comprehensive gain (loss) 933       933
Ending balance at Sep. 30, 2023 $ 600,681 $ 10 $ 2,190,587 $ (1,588,581) $ (1,335)
Ending balance (in shares) at Sep. 30, 2023   96,225,617      
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows used in operating activities    
Net loss $ (111,095) $ (212,230)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 392 513
Share-based compensation 37,976 31,854
Stock issued for services 69 68
Amortization of premiums and accretion of discounts on investment securities, net (5,861) (717)
Changes in operating assets and liabilities:    
Accounts receivable, net (27,481) (41,382)
Inventory (19,066) (15,649)
Prepaid expenses and other assets (16,805) (18,686)
Accounts payable 218 5,528
Accrued and other current liabilities 8,172 3,777
Accrued customer programs 9,997 13,982
Accrued employee benefits 2,452 253
Operating lease liabilities, net (1,106) 1,696
Net cash used in operating activities (122,138) (230,993)
Cash flows provided by (used in) investing activities    
Purchases of investments (310,805) (643,707)
Maturities of investments 369,192 465,877
Purchases of property and equipment (268) (806)
Net cash provided by (used in) investing activities 58,119 (178,636)
Cash flows provided by financing activities    
Proceeds of public offering, net 0 433,725
Proceeds from exercise of stock options 14,806 19,247
Net cash provided by financing activities 14,806 452,972
Net (decrease) increase in cash, cash equivalents, and restricted cash (49,213) 43,343
Cash, cash equivalents, and restricted cash at beginning of period 150,365 93,765
Cash, cash equivalents, and restricted cash at end of period 101,152 137,108
Non-cash investing and financing activities    
Right of use assets under operating leases $ 0 $ 5,375
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Statement of Cash Flows [Abstract]        
Cash and cash equivalents $ 99,402 $ 148,615 $ 135,358  
Restricted cash 1,750 1,750 1,750  
Total cash, cash equivalents and restricted cash $ 101,152 $ 150,365 $ 137,108 $ 93,765
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Organization
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder. In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
Recent Accounting Pronouncements
Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies
The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of September 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the nine-month period ended September 30, 2023, 97% of sales were from three major wholesalers accounting for approximately 36%, 32%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of September 30, 2023, the Company continues to believe that such customers are of high credit quality.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Investment Securities
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Investment Securities Investment Securities
Investment securities consisted of the following (in thousands):
September 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$191,726 $4 $(692)$191,038 
FDIC Certificates of Deposit5,131 — (40)5,091 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper81,594 — (150)81,444 
Corporate Notes/Bonds76,503 — (457)76,046 
$414,954 $4 $(1,339)$413,619 
December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$188,465 $14 $(1,729)$186,750 
FDIC Certificates of Deposit4,155 3 (72)4,086 
Certificates of Deposit7,500 — — 7,500 
Commercial Paper100,711 3 (269)100,445 
Corporate Notes/Bonds189,588 1 (2,141)187,448 
$490,419 $21 $(4,211)$486,229 
The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2023 and December 31, 2022, the Company held $41.2 million and $71.5 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year.
Unrealized losses as of September 30, 2023 approximate less than 1% of the estimated fair value of investments. The aggregate related fair value of investments with unrealized losses as of September 30, 2023 was $340.9 million, which consisted of $183.4 million from U.S. government agency securities, $5.1 million of certificates of deposit, $81.4 million of commercial paper, and $71.0 million of corporate notes/bonds. $58.9 million of the aggregate fair value of investments with unrealized losses as of September 30, 2023 has been held in a continuous unrealized loss position for over 12 months, with the remaining $282.0 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2022, the aggregate related fair value of investments with unrealized losses was $438.3 million. $49.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2022 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $389.2 million held in a continuous unrealized loss position for less than 12 months. The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company has no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2023 and December 31, 2022. The carrying value of cash held in money market funds of $4.4 million as of September 30, 2023 and $12.2 million as of December 31, 2022 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in certificates of deposit of $20.0 million as of September 30, 2023 is included in cash and cash equivalents. The carrying value of cash held in commercial paper of $14.9 million, U.S. government agency securities of $20.5 million and certificates of deposit of $7.5 million as of December 31, 2022 is included in cash and cash equivalents.
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
September 30,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$4,420 $4,420 $— $— 
U.S. Government Agency Securities191,038 — 191,038 — 
FDIC Certificates of Deposit5,091 — 5,091 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper81,444 — 81,444 — 
Corporate Notes/Bonds76,046 — 76,046 — 
$418,039 $4,420 $413,619 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$12,203 $12,203 $— $— 
U.S. Government Agency Securities186,750 — 186,750 — 
FDIC Certificates of Deposit4,086 — 4,086 — 
Certificates of Deposit7,500 — 7,500 — 
Commercial Paper100,445 — 100,445 — 
Corporate Notes/Bonds187,448 — 187,448 — 
$498,432 $12,203 $486,229 $— 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory consists of the following (in thousands):
September 30,
2023		December 31,
2022
Raw materials$33,173 $17,227 
Work in process4,773 2,594 
Finished goods5,040 4,099 
$42,986 $23,920 
The raw materials balance includes the active pharmaceutical ingredients (API) and any related intermediate compounds. This supply exceeds 12 months of forecasted sales and other needs.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Right of Use Assets and Lease Liabilities
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Right of Use Assets and Lease Liabilities Right of Use Assets and Lease Liabilities
In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029.
The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to obtain motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets.
The Company has no other significant leases. In addition, no identified leases require allocations between lease and non-lease components.
The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2023 and December 31, 2022 and operating cash outflows as of September 30, 2023 and 2022 (in thousands, except years and percentages):
September 30, 2023December 31, 2022
Other information
Weighted average remaining lease term5.6 years5.9 years
Weighted average discount rate9.07 %8.76 %
Nine Months Ended September 30,
20232022
Lease cost
Operating lease cost$2,921$4,139
Variable lease cost1,1301,218
Short-term lease cost1,757—
$5,808$5,357
Maturity analysis under the lease agreements is as follows (in thousands):
Three months ending December 31, 2023$930 
Year ending December 31, 20243,792 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Thereafter5,915 
Total22,540 
Less: Present value discount(5,065)
Total operating lease liability17,475 
Less: Current portion(3,584)
Operating lease liabilities, non-current$13,891 
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
License and Royalty Commitments
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company has made payments of $10.75 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of ten years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
Purchase Commitments
The Company enters into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. The Company recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of September 30, 2023, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory during 2023 and 2024. The Company has paid deposits of $19.4 million and $21.6 million as of September 30, 2023 and December 31, 2022, respectively, for the various campaigns, which are recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the nine-month periods ended September 30, 2023 and 2022, was comprised of the following (in thousands):
Nine Months Ended September 30,
20232022
Inventoriable costs$1,186 $1,307 
Selling, general and administrative25,269 19,293 
Research and development11,521 11,254 
Total share-based compensation expense$37,976 $31,854 
Information regarding the stock options activity, including with respect to grants to employees and directors as of September 30, 2023, and changes during the nine-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20224,785,972$26.27 5.8 years
Options granted 2023284,212
Options exercised 2023(645,977)
Options canceled or expired 2023(38,652)
Outstanding at September 30, 20234,385,555$27.96 
Vested and expected to vest at September 30, 20234,385,555$27.96 
Exercisable at September 30, 20233,605,710$23.37 
The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity and changes during the nine-month period ended September 30, 2023 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20221,274,664$42.76 0.8 years
Time-based RSUs granted in 20231,090,927
Time-based RSUs vested in 2023(657,775)
Time-based RSUs cancelled in 2023(60,148)
Outstanding at September 30, 20231,647,668$48.90 
As of September 30, 2023, there was $61.3 million of unrecognized compensation costs estimated related to unvested time-based RSUs.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Loss Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Loss Per Share Loss Per Share
The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2023 and 2022:
Three and Nine Months Ended
September 30,
20232022
Stock options4,385,5554,926,117
RSUs1,755,4601,495,711
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure                
Net loss $ (24,258) $ (42,784) $ (44,053) $ (53,508) $ (86,603) $ (72,119) $ (111,095) $ (212,230)
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended 9 Months Ended
Sep. 30, 2023
shares
Sep. 30, 2023
shares
Trading Arrangements, by Individual    
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Michael I. Halstead [Member]    
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   •On August 11, 2023, Michael I. Halstead, Executive Vice President, General Counsel and Secretary, modified his Rule 10b5-1 Trading Plan, originally adopted on March 15, 2023 and modified on May 8, 2023, to change the start date of the plan to November 13, 2023, and increase the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 137,872 shares of our common stock until March 28, 2024.
Name Michael I. Halstead  
Title Executive Vice President, General Counsel and Secretary  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date August 11, 2023  
Arrangement Duration 136 days  
Aggregate Available 137,872 137,872
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders.
Recent Accounting Pronouncements Recent Accounting Pronouncements Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.
Use of Estimates Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies Significant Accounting Policies The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Concentration of Credit Risk Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of September 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the nine-month period ended September 30, 2023, 97% of sales were from three major wholesalers accounting for approximately 36%, 32%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of September 30, 2023, the Company continues to believe that such customers are of high credit quality.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Investment Securities (Tables)
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment Securities
Investment securities consisted of the following (in thousands):
September 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$191,726 $4 $(692)$191,038 
FDIC Certificates of Deposit5,131 — (40)5,091 
Certificates of Deposit60,000 — — 60,000 
Commercial Paper81,594 — (150)81,444 
Corporate Notes/Bonds76,503 — (457)76,046 
$414,954 $4 $(1,339)$413,619 
December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
(Losses)		Estimated
Fair
Value
U.S. Government Agency Securities$188,465 $14 $(1,729)$186,750 
FDIC Certificates of Deposit4,155 3 (72)4,086 
Certificates of Deposit7,500 — — 7,500 
Commercial Paper100,711 3 (269)100,445 
Corporate Notes/Bonds189,588 1 (2,141)187,448 
$490,419 $21 $(4,211)$486,229 
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities
The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):
Fair Value Measurements at
Reporting Date Using
September 30,
2023		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$4,420 $4,420 $— $— 
U.S. Government Agency Securities191,038 — 191,038 — 
FDIC Certificates of Deposit5,091 — 5,091 — 
Certificates of Deposit60,000 — 60,000 — 
Commercial Paper81,444 — 81,444 — 
Corporate Notes/Bonds76,046 — 76,046 — 
$418,039 $4,420 $413,619 $— 
Fair Value Measurements at
Reporting Date Using
December 31,
2022		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Money Market Funds$12,203 $12,203 $— $— 
U.S. Government Agency Securities186,750 — 186,750 — 
FDIC Certificates of Deposit4,086 — 4,086 — 
Certificates of Deposit7,500 — 7,500 — 
Commercial Paper100,445 — 100,445 — 
Corporate Notes/Bonds187,448 — 187,448 — 
$498,432 $12,203 $486,229 $— 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Inventory consists of the following (in thousands):
September 30,
2023		December 31,
2022
Raw materials$33,173 $17,227 
Work in process4,773 2,594 
Finished goods5,040 4,099 
$42,986 $23,920 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Right of Use Assets and Lease Liabilities (Tables)
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Schedule of Quantitative Information About Operating Leases
The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2023 and December 31, 2022 and operating cash outflows as of September 30, 2023 and 2022 (in thousands, except years and percentages):
September 30, 2023December 31, 2022
Other information
Weighted average remaining lease term5.6 years5.9 years
Weighted average discount rate9.07 %8.76 %
Nine Months Ended September 30,
20232022
Lease cost
Operating lease cost$2,921$4,139
Variable lease cost1,1301,218
Short-term lease cost1,757—
$5,808$5,357
Schedule Of Maturity Analysis Under Lease Agreements
Maturity analysis under the lease agreements is as follows (in thousands):
Three months ending December 31, 2023$930 
Year ending December 31, 20243,792 
Year ending December 31, 20253,907 
Year ending December 31, 20263,974 
Year ending December 31, 20274,022 
Thereafter5,915 
Total22,540 
Less: Present value discount(5,065)
Total operating lease liability17,475 
Less: Current portion(3,584)
Operating lease liabilities, non-current$13,891 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount
Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the nine-month periods ended September 30, 2023 and 2022, was comprised of the following (in thousands):
Nine Months Ended September 30,
20232022
Inventoriable costs$1,186 $1,307 
Selling, general and administrative25,269 19,293 
Research and development11,521 11,254 
Total share-based compensation expense$37,976 $31,854 
Stock Option Activity
Information regarding the stock options activity, including with respect to grants to employees and directors as of September 30, 2023, and changes during the nine-month period then ended, are summarized as follows:
Number of
Shares		Weighted-
Average
Exercise
Price		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20224,785,972$26.27 5.8 years
Options granted 2023284,212
Options exercised 2023(645,977)
Options canceled or expired 2023(38,652)
Outstanding at September 30, 20234,385,555$27.96 
Vested and expected to vest at September 30, 20234,385,555$27.96 
Exercisable at September 30, 20233,605,710$23.37 
Summary of Information Regarding RSU Activity Information regarding the time-based RSU activity and changes during the nine-month period ended September 30, 2023 is summarized as follows:
Number of
Shares		Weighted-Average
Grant Date
Fair Value Per Share		Weighted-
Average
Contractual
Life
Outstanding at December 31, 20221,274,664$42.76 0.8 years
Time-based RSUs granted in 20231,090,927
Time-based RSUs vested in 2023(657,775)
Time-based RSUs cancelled in 2023(60,148)
Outstanding at September 30, 20231,647,668$48.90 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Loss Per Share - (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share
The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2023 and 2022:
Three and Nine Months Ended
September 30,
20232022
Stock options4,385,5554,926,117
RSUs1,755,4601,495,711
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Additional Information (Detail)
 9 Months Ended
Sep. 30, 2023
Segment
Significant Accounting Policies [Line Items]  
Number of operating segments 1
Revenue Benchmark | Customer Concentration Risk | Three Major Wholesalers  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 97.00%
Revenue Benchmark | Customer Concentration Risk | Customer One  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 36.00%
Revenue Benchmark | Customer Concentration Risk | Customer Two  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 32.00%
Revenue Benchmark | Customer Concentration Risk | Customer Three  
Significant Accounting Policies [Line Items]  
Concentration risk (as a percent) 29.00%
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Investment Securities - Summary of Investment Securities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost $ 414,954 $ 490,419
Unrealized Gains 4 21
Unrealized (Losses) (1,339) (4,211)
Estimated Fair Value 413,619 486,229
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 191,726 188,465
Unrealized Gains 4 14
Unrealized (Losses) (692) (1,729)
Estimated Fair Value 191,038 186,750
FDIC Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 5,131 4,155
Unrealized Gains 0 3
Unrealized (Losses) (40) (72)
Estimated Fair Value 5,091 4,086
Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 60,000 7,500
Unrealized Gains 0 0
Unrealized (Losses) 0 0
Estimated Fair Value 60,000 7,500
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 81,594 100,711
Unrealized Gains 0 3
Unrealized (Losses) (150) (269)
Estimated Fair Value 81,444 100,445
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 76,503 189,588
Unrealized Gains 0 1
Unrealized (Losses) (457) (2,141)
Estimated Fair Value $ 76,046 $ 187,448
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Investment Securities - Additional Information (Detail)
$ in Millions
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Debt Securities, Available-for-Sale [Line Items]    
Investment securities, available for sale, noncurrent $ 41.2 $ 71.5
Percentage of fair value instruments 0.01  
Aggregate related fair value of investments with unrealized losses $ 340.9 438.3
Aggregate fair value of investments with unrealized losses 58.9 49.1
Continuous unrealized losses, value remaining 282.0 $ 389.2
U.S. Government Agency Securities    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 183.4  
Certificates of Deposit    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 5.1  
Commercial Paper    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses 81.4  
Corporate Notes/Bonds    
Debt Securities, Available-for-Sale [Line Items]    
Aggregate related fair value of investments with unrealized losses $ 71.0  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying value of cash held in money market funds $ 4.4 $ 12.2
Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Certificates of deposits 20.0 7.5
Commercial paper value listed as cash equivalent   14.9
Carrying value of cash held in commercial paper, government securities   20.5
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities measured using quoted prices 0.0 0.0
Assets measured using quoted prices $ 0.0 $ 0.0
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 418,039 $ 498,432
Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 4,420 12,203
Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 191,038 186,750
Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 5,091 4,086
Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 60,000 7,500
Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 81,444 100,445
Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 76,046 187,448
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 4,420 12,203
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 4,420 12,203
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 413,619 486,229
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 191,038 186,750
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 5,091 4,086
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 60,000 7,500
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 81,444 100,445
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 76,046 187,448
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | U.S. Government Agency Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | FDIC Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Commercial Paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities 0 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate Notes/Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale investment securities $ 0 $ 0
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory - Schedule of Inventory, Current (Detail) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 33,173 $ 17,227
Work in process 4,773 2,594
Finished goods 5,040 4,099
Total inventories $ 42,986 $ 23,920
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Right of Use Assets and Lease Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Sep. 30, 2018
Vehicle Lease    
Operating Leased Assets [Line Items]    
Term of long term lease 12 months  
Guarantor obligations, value $ 1,750  
NEW YORK    
Operating Leased Assets [Line Items]    
Term of long term lease   14 years 3 months 18 days
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Other information      
Weighted average remaining lease term (in years) 5 years 7 months 6 days   5 years 10 months 24 days
Weighted average discount rate (as a percent) 9.07%   8.76%
Lease cost      
Operating lease cost $ 2,921 $ 4,139  
Variable lease cost 1,130 1,218  
Short-term lease cost 1,757 0  
Total lease cost $ 5,808 $ 5,357  
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Three months ending December 31, 2023 $ 930  
Year ending December 31, 2024 3,792  
Year ending December 31, 2025 3,907  
Year ending December 31, 2026 3,974  
Year ending December 31, 2027 4,022  
Thereafter 5,915  
Total 22,540  
Less: Present value discount (5,065)  
Total operating lease liability 17,475  
Less: Current portion (3,584) $ (4,567)
Operating lease liabilities, non-current $ 13,891 $ 15,474
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 9 Months Ended 220 Months Ended
May 31, 2005
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Purchase Commitment        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Cash paid   $ 19,400 $ 19,400 $ 21,600
Product | Bristol-Myers Squibb Company        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Company made an upfront payment     10,750  
Payment of milestone amount   $ 5,000 $ 5,000  
Obliged to make milestone payments $ 14,750      
License expiration period   10 years    
Product | Bristol-Myers Squibb Company | Minimum        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Royalty payment, percentage (as a percent) 5.00%      
Product | Bristol-Myers Squibb Company | Maximum        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Royalty payment, percentage (as a percent) 9.00%      
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense $ 37,976 $ 31,854
Inventoriable costs    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense 1,186 1,307
Selling, general and administrative    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense 25,269 19,293
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Total share-based compensation expense $ 11,521 $ 11,254
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Stock Options Activity (Detail) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]    
Outstanding at beginning of period, Number of Shares (in shares) 4,785,972  
Options granted, Number of Shares (in shares) 284,212  
Options exercised, Number of Shares (in shares) (645,977)  
Options canceled or expired, Number of Shares (in shares) (38,652)  
Outstanding at end of period, Number of Shares (in shares) 4,385,555 4,785,972
Vested or expected to vest at end of period, Number of Shares (in shares) 4,385,555  
Exercisable at end of period, Number of Shares (in shares) 3,605,710  
Weighted- Average Exercise Price    
Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share) $ 26.27  
Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share) 27.96 $ 26.27
Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share) 27.96  
Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share) $ 23.37  
Outstanding at end of period, Weighted-Average Contractual Life (in years)   5 years 9 months 18 days
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - RSUs - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]    
Outstanding at beginning of year, Number of Shares (in shares) 1,274,664  
Time based RSU's granted, Number of Shares (in shares) 1,090,927  
Time based RSU's vested, Number of Shares (in shares) (657,775)  
Time based RSU's cancelled, Number of Shares (in shares) (60,148)  
Outstanding at end of year, Number of Shares (in shares) 1,647,668 1,274,664
Weighted-Average Grant Date Fair Value Per Share    
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 42.76  
Time based RSU's granted, Weighted-Average Grant Date Fair Value (in dollars per share)  
Time based RSU's vested, Weighted-Average Grant Date Fair Value (in dollars per share)  
Time based RSU's cancelled, Weighted-Average Grant Date Fair Value (in dollars per share)  
Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share) $ 48.90 $ 42.76
Restricted stock outstanding, Weighted-Average Contractual Life (in years) 9 months 18 days
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Additional Information (Detail)
$ in Millions
Sep. 30, 2023
USD ($)
Time Based Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation costs related to unvested RSUs $ 61.3
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 4,385,555 4,926,117 4,385,555 4,926,117
RSUs        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Number of anti-dilutive securities excluded from computation of earnings per share (in shares) 1,755,460 1,495,711 1,755,460 1,495,711
XML 51 itci-20230930_htm.xml IDEA: XBRL DOCUMENT 0001567514 2023-01-01 2023-09-30 0001567514 2023-10-31 0001567514 2023-09-30 0001567514 2022-12-31 0001567514 us-gaap:ProductMember 2023-07-01 2023-09-30 0001567514 us-gaap:ProductMember 2022-07-01 2022-09-30 0001567514 us-gaap:ProductMember 2023-01-01 2023-09-30 0001567514 us-gaap:ProductMember 2022-01-01 2022-09-30 0001567514 us-gaap:GrantMember 2023-07-01 2023-09-30 0001567514 us-gaap:GrantMember 2022-07-01 2022-09-30 0001567514 us-gaap:GrantMember 2023-01-01 2023-09-30 0001567514 us-gaap:GrantMember 2022-01-01 2022-09-30 0001567514 2023-07-01 2023-09-30 0001567514 2022-07-01 2022-09-30 0001567514 2022-01-01 2022-09-30 0001567514 us-gaap:CommonStockMember 2021-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001567514 us-gaap:RetainedEarningsMember 2021-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001567514 2021-12-31 0001567514 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001567514 2022-01-01 2022-03-31 0001567514 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001567514 us-gaap:CommonStockMember 2022-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001567514 us-gaap:RetainedEarningsMember 2022-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001567514 2022-03-31 0001567514 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001567514 2022-04-01 2022-06-30 0001567514 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001567514 us-gaap:CommonStockMember 2022-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001567514 us-gaap:RetainedEarningsMember 2022-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001567514 2022-06-30 0001567514 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001567514 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001567514 us-gaap:CommonStockMember 2022-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001567514 us-gaap:RetainedEarningsMember 2022-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001567514 2022-09-30 0001567514 us-gaap:CommonStockMember 2022-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001567514 us-gaap:RetainedEarningsMember 2022-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001567514 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001567514 2023-01-01 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-03-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001567514 us-gaap:RetainedEarningsMember 2023-03-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001567514 2023-03-31 0001567514 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001567514 2023-04-01 2023-06-30 0001567514 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001567514 us-gaap:CommonStockMember 2023-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001567514 us-gaap:RetainedEarningsMember 2023-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001567514 2023-06-30 0001567514 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001567514 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001567514 us-gaap:CommonStockMember 2023-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001567514 us-gaap:RetainedEarningsMember 2023-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001567514 itci:ThreeMajorWholesalersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001567514 itci:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001567514 itci:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001567514 itci:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001567514 itci:FDICCertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:CertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:CommercialPaperMember 2023-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001567514 us-gaap:CashAndCashEquivalentsMember 2023-09-30 0001567514 us-gaap:CashAndCashEquivalentsMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember itci:FDICCertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001567514 stpr:NY 2018-09-30 0001567514 us-gaap:VehiclesMember 2023-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 2023-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2023-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MinimumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MaximumMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2023-01-01 2023-09-30 0001567514 us-gaap:PurchaseCommitmentMember 2023-09-30 0001567514 us-gaap:PurchaseCommitmentMember 2022-12-31 0001567514 itci:InventoriableCostsMember 2023-01-01 2023-09-30 0001567514 itci:InventoriableCostsMember 2022-01-01 2022-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001567514 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001567514 2022-01-01 2022-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2023-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001567514 itci:MichaelIHalsteadMember 2023-01-01 2023-09-30 0001567514 itci:MichaelIHalsteadMember 2023-07-01 2023-09-30 0001567514 itci:MichaelIHalsteadMember 2023-09-30 shares iso4217:USD iso4217:USD shares itci:Segment pure 0001567514 --12-31 2023 Q3 false P136D 10-Q true 2023-09-30 false 001-36274 INTRA-CELLULAR THERAPIES, INC. DE 36-4742850 430 East 29th Street New York NY 10016 646 440-9333 Common Stock ITCI NASDAQ Yes Yes Large Accelerated Filer false false false 96238126 99402000 148615000 393619000 443290000 1750000 1750000 102670000 75189000 42986000 23920000 61998000 45193000 702425000 737957000 1789000 1913000 13364000 14824000 86000 86000 717664000 754780000 10613000 10395000 27829000 19657000 35618000 25621000 25448000 22996000 3584000 4567000 103092000 83236000 13891000 15474000 116983000 98710000 0.0001 0.0001 175000000 175000000 96225617 96225617 94829794 94829794 10000 9000 2190587000 2137737000 -1588581000 -1477486000 -1335000 -4190000 600681000 656070000 717664000 754780000 125810000 71870000 330669000 161699000 363000 0 1602000 746000 126173000 71870000 332271000 162445000 9129000 5850000 23043000 13655000 105207000 88375000 305144000 264151000 41550000 33274000 129368000 100853000 155886000 127499000 457555000 378659000 -29713000 -55629000 -125284000 -216214000 5498000 2122000 14377000 3990000 -24215000 -53507000 -110907000 -212224000 43000 1000 188000 6000 -24258000 -53508000 -111095000 -212230000 -0.25 -0.25 -0.57 -0.57 -1.16 -1.16 -2.26 -2.26 96143083 96143083 94516794 94516794 95745641 95745641 93809124 93809124 -24258000 -53508000 -111095000 -212230000 933000 -694000 2855000 -5132000 -23325000 -54202000 -108240000 -217362000 81886965 8000 1639476000 -1221230000 -364000 417890000 10952381 1000 433724000 433725000 1180696 8089000 8089000 383 24000 24000 8105000 8105000 -72119000 -72119000 -2964000 -2964000 94020425 9000 2089418000 -1293349000 -3328000 792750000 346411 5504000 5504000 397 22000 22000 11998000 11998000 -86603000 -86603000 -1474000 -1474000 94367233 9000 2106942000 -1379952000 -4802000 722197000 333954 5654000 5654000 475 22000 22000 11751000 11751000 -53508000 -53508000 -694000 -694000 94701662 9000 2124369000 -1433460000 -5496000 685422000 94829794 9000 2137737000 -1477486000 -4190000 656070000 849827 1000 3639000 3640000 408 22000 22000 10439000 10439000 -44053000 -44053000 1492000 1492000 95680029 10000 2151837000 -1521539000 -2698000 627610000 402994 8585000 8585000 364 23000 23000 13226000 13226000 -42784000 -42784000 430000 430000 96083387 10000 2173671000 -1564323000 -2268000 607090000 141780 2581000 2581000 450 24000 24000 14311000 14311000 -24258000 -24258000 933000 933000 96225617 10000 2190587000 -1588581000 -1335000 600681000 -111095000 -212230000 392000 513000 37976000 31854000 69000 68000 5861000 717000 27481000 41382000 19066000 15649000 16805000 18686000 218000 5528000 8172000 3777000 -9997000 -13982000 2452000 253000 -1106000 1696000 -122138000 -230993000 310805000 643707000 369192000 465877000 268000 806000 58119000 -178636000 0 433725000 14806000 19247000 14806000 452972000 -49213000 43343000 150365000 93765000 101152000 137108000 0 5375000 99402000 135358000 1750000 1750000 101152000 137108000 Organization Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression in December 2021. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. Lumateperone is in Phase 3 clinical development as a novel treatment for major depressive disorder. In order to further its commercial activities and research projects and support its collaborations, the Company may require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt or convertible debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s products, product candidates and technology and, to a much lesser extent, grant funding. Summary of Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div>Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of September 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the nine-month period ended September 30, 2023, 97% of sales were from three major wholesalers accounting for approximately 36%, 32%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of September 30, 2023, the Company continues to believe that such customers are of high credit quality. Basis of Presentation The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily for the treatment of neurological and psychiatric disorders. 1 1 Recent Accounting Pronouncements Management has evaluated all accounting pronouncements issued through the date of the condensed consolidated financial statements and does not believe that any recently issued, but not yet effective, pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. Significant Accounting Policies The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investments held at financial institutions. As of September 30, 2023, the majority of the Company’s accounts receivable, net arose from product sales in the United States. For the nine-month period ended September 30, 2023, 97% of sales were from three major wholesalers accounting for approximately 36%, 32%, and 29% of product sales. The percentage of the total net product sales by individual customers has not significantly changed since inception. All customers have standard payment terms which generally require payment within 60 days. As of September 30, 2023, the Company continues to believe that such customers are of high credit quality. 0.97 0.36 0.32 0.29 Investment Securities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(692)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">414,954</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,339)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">413,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490,419 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2023 and December 31, 2022, the Company held $41.2 million and $71.5 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year. </span></div>Unrealized losses as of September 30, 2023 approximate less than 1% of the estimated fair value of investments. The aggregate related fair value of investments with unrealized losses as of September 30, 2023 was $340.9 million, which consisted of $183.4 million from U.S. government agency securities, $5.1 million of certificates of deposit, $81.4 million of commercial paper, and $71.0 million of corporate notes/bonds. $58.9 million of the aggregate fair value of investments with unrealized losses as of September 30, 2023 has been held in a continuous unrealized loss position for over 12 months, with the remaining $282.0 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2022, the aggregate related fair value of investments with unrealized losses was $438.3 million. $49.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2022 had been held in a continuous unrealized loss position for over than 12 months, with the remaining $389.2 million held in a continuous unrealized loss position for less than 12 months. The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(692)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,594</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">414,954</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,339)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">413,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized<br/>(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">188,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490,419 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 191726000 4000 692000 191038000 5131000 0 40000 5091000 60000000 0 0 60000000 81594000 0 150000 81444000 76503000 0 457000 76046000 414954000 4000 1339000 413619000 188465000 14000 1729000 186750000 4155000 3000 72000 4086000 7500000 0 0 7500000 100711000 3000 269000 100445000 189588000 1000 2141000 187448000 490419000 21000 4211000 486229000 41200000 71500000 0.01 340900000 183400000 5100000 81400000 71000000 58900000 282000000 438300000 49100000 389200000 Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value method under ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2023 and December 31, 2022. The carrying value of cash held in money market funds of $4.4 million as of September 30, 2023 and $12.2 million as of December 31, 2022 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in certificates of deposit of $20.0 million as of September 30, 2023 is included in cash and cash equivalents. The carrying value of cash held in commercial paper of $14.9 million, U.S. government agency securities of $20.5 million and certificates of deposit of $7.5 million as of December 31, 2022 is included in cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">418,039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">413,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">498,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 0 4400000 12200000 20000000 14900000 20500000 7500000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">191,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,091</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">60,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">81,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">76,046</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">418,039</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,420</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">413,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government Agency Securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDIC Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,445 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Notes/Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">498,432 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4420000 4420000 0 0 191038000 0 191038000 0 5091000 0 5091000 0 60000000 0 60000000 0 81444000 0 81444000 0 76046000 0 76046000 0 418039000 4420000 413619000 0 12203000 12203000 0 0 186750000 0 186750000 0 4086000 0 4086000 0 7500000 0 7500000 0 100445000 0 100445000 0 187448000 0 187448000 0 498432000 12203000 486229000 0 Inventory <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">42,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,920 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The raw materials balance includes the active pharmaceutical ingredients (API) and any related intermediate compounds. This supply exceeds 12 months of forecasted sales and other needs.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33,173</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,040</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">42,986</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,920 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33173000 17227000 4773000 2594000 5040000 4099000 42986000 23920000 Right of Use Assets and Lease Liabilities <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to obtain motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease, which has been recorded as restricted cash on the condensed consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no other significant leases. In addition, no identified leases require allocations between lease and non-lease components. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2023 and December 31, 2022 and operating cash outflows as of September 30, 2023 and 2022 (in thousands, except years and percentages): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,921</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,139</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,218</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,808</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,357</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analysis under the lease agreements is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ending December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,584)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P14Y3M18D P12M P12M 1750000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the lease balances within the condensed consolidated balance sheets, weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2023 and December 31, 2022 and operating cash outflows as of September 30, 2023 and 2022 (in thousands, except years and percentages): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,921</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,139</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,218</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,808</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,357</span></td></tr></table></div> P5Y7M6D P5Y10M24D 0.0907 0.0876 2921000 4139000 1130000 1218000 1757000 0 5808000 5357000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity analysis under the lease agreements is as follows (in thousands): </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ending December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ending December 31, 2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,584)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,891 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 930000 3792000 3907000 3974000 4022000 5915000 22540000 5065000 17475000 3584000 13891000 Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Royalty Commitments </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company has made payments of $10.75 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of ten years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments </span></div>The Company enters into certain other long-term commitments for goods and services that are outstanding for periods greater than one year. The Company recently amended certain manufacturing service agreements committing the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of September 30, 2023, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (API) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory during 2023 and 2024. The Company has paid deposits of $19.4 million and $21.6 million as of September 30, 2023 and December 31, 2022, respectively, for the various campaigns, which are recorded within prepaid expenses and other current assets. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan within the executed agreements. 10750000 5000000 14750000 0.05 0.09 P10Y 19400000 21600000 Share-Based Compensation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the nine-month periods ended September 30, 2023 and 2022, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">37,976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors as of September 30, 2023, and changes during the nine-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,785,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">284,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(645,977)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,652)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385,555</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385,555</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.96 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,605,710</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.37 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity and changes during the nine-month period ended September 30, 2023 is summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,274,664</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,090,927</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(657,775)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60,148)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,647,668</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.90 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div>As of September 30, 2023, there was $61.3 million of unrecognized compensation costs estimated related to unvested time-based RSUs. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (RSUs) granted to employees and directors recognized during the nine-month periods ended September 30, 2023 and 2022, was comprised of the following (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventoriable costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,521</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">37,976</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1186000 1307000 25269000 19293000 11521000 11254000 37976000 31854000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the stock options activity, including with respect to grants to employees and directors as of September 30, 2023, and changes during the nine-month period then ended, are summarized as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,785,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">284,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(645,977)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,652)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385,555</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,385,555</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.96 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,605,710</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.37 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 4785972 26.27 P5Y9M18D 284212 645977 38652 4385555 27.96 4385555 27.96 3605710 23.37 Information regarding the time-based RSU activity and changes during the nine-month period ended September 30, 2023 is summarized as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average<br/>Grant Date<br/>Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Contractual<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,274,664</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs granted in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,090,927</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs vested in 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(657,775)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time-based RSUs cancelled in 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60,148)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,647,668</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.90 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> 1274664 42.76 P0Y9M18D 1090927 657775 60148 1647668 48.90 61300000 Loss Per Share <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2023 and 2022: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,385,555</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,926,117</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,755,460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,495,711</span></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following share-based awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2023 and 2022: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three and Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,385,555</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,926,117</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,755,460</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,495,711</span></td></tr></table></div> 4385555 4385555 4926117 4926117 1755460 1755460 1495711 1495711 false <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">On August 11, 2023, Michael I. Halstead, Executive Vice President, General Counsel and Secretary, modified his Rule 10b5-1 Trading Plan, originally adopted on March 15, 2023 and modified on May 8, 2023, to change the start date of the plan to November 13, 2023, and increase the number of shares to be sold under the plan. The modified plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 137,872 shares of our common stock until March 28, 2024.</span> August 11, 2023 Michael I. Halstead Executive Vice President, General Counsel and Secretary true 137872 false false EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 188 204 1 false 42 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.intracellulartherapies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 8 false false R9.htm 0000009 - Disclosure - Organization Sheet http://www.intracellulartherapies.com/role/Organization Organization Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Investment Securities Sheet http://www.intracellulartherapies.com/role/InvestmentSecurities Investment Securities Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value Measurements Sheet http://www.intracellulartherapies.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Inventory Sheet http://www.intracellulartherapies.com/role/Inventory Inventory Notes 13 false false R14.htm 0000014 - Disclosure - Right of Use Assets and Lease Liabilities Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities Right of Use Assets and Lease Liabilities Notes 14 false false R15.htm 0000015 - Disclosure - Commitments and Contingencies Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Share-Based Compensation Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensation Share-Based Compensation Notes 16 false false R17.htm 0000017 - Disclosure - Loss Per Share Sheet http://www.intracellulartherapies.com/role/LossPerShare Loss Per Share Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 9954472 - Disclosure - Investment Securities (Tables) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables Investment Securities (Tables) Tables http://www.intracellulartherapies.com/role/InvestmentSecurities 21 false false R22.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.intracellulartherapies.com/role/FairValueMeasurements 22 false false R23.htm 9954474 - Disclosure - Inventory (Tables) Sheet http://www.intracellulartherapies.com/role/InventoryTables Inventory (Tables) Tables http://www.intracellulartherapies.com/role/Inventory 23 false false R24.htm 9954475 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables Right of Use Assets and Lease Liabilities (Tables) Tables http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities 24 false false R25.htm 9954476 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.intracellulartherapies.com/role/ShareBasedCompensation 25 false false R26.htm 9954477 - Disclosure - Loss Per Share - (Tables) Sheet http://www.intracellulartherapies.com/role/LossPerShareTables Loss Per Share - (Tables) Tables http://www.intracellulartherapies.com/role/LossPerShare 26 false false R27.htm 9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 27 false false R28.htm 9954479 - Disclosure - Investment Securities - Summary of Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail Investment Securities - Summary of Investment Securities (Detail) Details 28 false false R29.htm 9954480 - Disclosure - Investment Securities - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail Investment Securities - Additional Information (Detail) Details 29 false false R30.htm 9954481 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 30 false false R31.htm 9954482 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Sheet http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) Details 31 false false R32.htm 9954483 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) Sheet http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail Inventory - Schedule of Inventory, Current (Detail) Details 32 false false R33.htm 9954484 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails Right of Use Assets and Lease Liabilities - Additional Information (Details) Details 33 false false R34.htm 9954485 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Details 34 false false R35.htm 9954486 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Sheet http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Details 35 false false R36.htm 9954487 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 36 false false R37.htm 9954488 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Details 37 false false R38.htm 9954489 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail Share-Based Compensation - Stock Options Activity (Detail) Details 38 false false R39.htm 9954490 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Details 39 false false R40.htm 9954491 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 40 false false R41.htm 9954492 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Sheet http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Details 41 false false All Reports Book All Reports itci-20230930.htm itci-20230930.xsd itci-20230930_cal.xml itci-20230930_def.xml itci-20230930_lab.xml itci-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "itci-20230930.htm": { "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20230930", "dts": { "inline": { "local": [ "itci-20230930.htm" ] }, "schema": { "local": [ "itci-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "itci-20230930_cal.xml" ] }, "definitionLink": { "local": [ "itci-20230930_def.xml" ] }, "labelLink": { "local": [ "itci-20230930_lab.xml" ] }, "presentationLink": { "local": [ "itci-20230930_pre.xml" ] } }, "keyStandard": 191, "keyCustom": 13, "axisStandard": 19, "axisCustom": 0, "memberStandard": 27, "memberCustom": 9, "hidden": { "total": 6, "http://xbrl.sec.gov/ecd/2023": 1, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 188, "entityCount": 1, "segmentCount": 42, "elementCount": 410, "unitCount": 5, "baseTaxonomies": { "http://xbrl.sec.gov/ecd/2023": 10, "http://fasb.org/us-gaap/2023": 536, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.intracellulartherapies.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R3": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R6": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R7": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-49", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R9": { "role": "http://www.intracellulartherapies.com/role/Organization", "longName": "0000009 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecurities", "longName": "0000011 - Disclosure - Investment Securities", "shortName": "Investment Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurements", "longName": "0000012 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.intracellulartherapies.com/role/Inventory", "longName": "0000013 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities", "longName": "0000014 - Disclosure - Right of Use Assets and Lease Liabilities", "shortName": "Right of Use Assets and Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "itci:RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingencies", "longName": "0000015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensation", "longName": "0000016 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.intracellulartherapies.com/role/LossPerShare", "longName": "0000017 - Disclosure - Loss Per Share", "shortName": "Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-13", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables", "longName": "9954472 - Disclosure - Investment Securities (Tables)", "shortName": "Investment Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.intracellulartherapies.com/role/InventoryTables", "longName": "9954474 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables", "longName": "9954475 - Disclosure - Right of Use Assets and Lease Liabilities (Tables)", "shortName": "Right of Use Assets and Lease Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "longName": "9954476 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.intracellulartherapies.com/role/LossPerShareTables", "longName": "9954477 - Disclosure - Loss Per Share - (Tables)", "shortName": "Loss Per Share - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954478 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail", "longName": "9954479 - Disclosure - Investment Securities - Summary of Investment Securities (Detail)", "shortName": "Investment Securities - Summary of Investment Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "longName": "9954480 - Disclosure - Investment Securities - Additional Information (Detail)", "shortName": "Investment Securities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "longName": "9954481 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "longName": "9954482 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "shortName": "Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-124", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail", "longName": "9954483 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)", "shortName": "Inventory - Schedule of Inventory, Current (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails", "longName": "9954484 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Details)", "shortName": "Right of Use Assets and Lease Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-157", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "longName": "9954485 - Disclosure - Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "shortName": "Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "itci:ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail", "longName": "9954486 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "shortName": "Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "longName": "9954487 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-164", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R37": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "longName": "9954488 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "shortName": "Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-166", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R38": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "longName": "9954489 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)", "shortName": "Share-Based Compensation - Stock Options Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R39": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "longName": "9954490 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-173", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-175", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "unique": true } }, "R40": { "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "longName": "9954491 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "shortName": "Share-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-177", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "longName": "9954492 - Disclosure - Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "shortName": "Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-178", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "itci-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.0001 par value: 175,000,000 shares authorized at September\u00a030, 2023 and December\u00a031, 2022; 96,225,617 and 94,829,794 shares issued and outstanding at September\u00a030, 2023 and December\u00a031, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r49", "r373", "r516" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "verboseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r538", "r549", "r559", "r584" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r54", "r81", "r376", "r516", "r626", "r638", "r653" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r605" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r537", "r548", "r558", "r583" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r630" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers." } } }, "auth_ref": [ "r47", "r80" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r47", "r80" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r542", "r553", "r563", "r580", "r588" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r530" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r11", "r16", "r106", "r109", "r113", "r314", "r315", "r320", "r366", "r381", "r621", "r622" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r68", "r119" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r32", "r33", "r34", "r88", "r89", "r91", "r92" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r11", "r48", "r49", "r74", "r406", "r462", "r482", "r528" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in share)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r138", "r143" ] }, "itci_DebtSecuritiesAvailableForSaleUnrealizedLossesPercentageOfFairValueOfInvestments": { "xbrltype": "pureItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossesPercentageOfFairValueOfInvestments", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair value instruments", "label": "Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments", "documentation": "Debt Securities, Available For Sale, Unrealized Losses, Percentage Of Fair Value Of Investments" } } }, "auth_ref": [] }, "itci_IncreaseDecreaseInAccruedCustomerPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "IncreaseDecreaseInAccruedCustomerPrograms", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued customer programs", "label": "Increase Decrease In Accrued Customer Programs", "documentation": "Increase decrease in accrued customer programs." } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r591" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "itci_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "CustomerThreeMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Three", "label": "Customer Three [Member]", "documentation": "Customer three." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r532" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r137", "r143" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of cash held in money market funds", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options and issuances of restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r11", "r74" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r648" ] }, "itci_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "CustomerOneMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One", "label": "Customer One [Member]", "documentation": "Customer one." } } }, "auth_ref": [] }, "itci_OtherInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "OtherInformationAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Other information", "label": "Other Information [Abstract]", "documentation": "Other information." } } }, "auth_ref": [] }, "itci_TimeBasedRestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "TimeBasedRestrictedStockUnitsRSUMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Time Based Restricted Stock Units", "label": "Time Based Restricted Stock Units R S U [Member]", "documentation": "Time based restricted stock units." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r164", "r507", "r646", "r666", "r667" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r48", "r49", "r74", "r403", "r462", "r482" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r239", "r246", "r274", "r275", "r276", "r339", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r521", "r639", "r645", "r659", "r660", "r661", "r662", "r663" ] }, "itci_CollaborativeArrangementLicenseExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "CollaborativeArrangementLicenseExpirationTerm", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License expiration period", "label": "Collaborative Arrangement License Expiration Term", "documentation": "Collaborative arrangement license expiration description." } } }, "auth_ref": [] }, "itci_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "SignificantAccountingPoliciesLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r536", "r547", "r557", "r582" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r608", "r624" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "itci_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "CustomerTwoMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Two", "label": "Customer Two [Member]", "documentation": "Customer two." } } }, "auth_ref": [] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r538", "r549", "r559", "r584" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r73", "r523", "r524", "r525", "r526" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r246", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r645", "r658", "r659", "r660", "r661", "r662", "r663" ] }, "itci_FDICCertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "FDICCertificatesOfDepositMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "FDIC Certificates of Deposit", "label": "FDIC Certificates Of Deposit [Member]", "documentation": "FDIC certificates of deposit." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r239", "r246", "r274", "r275", "r276", "r339", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r521", "r639", "r645", "r659", "r660", "r661", "r662", "r663" ] }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsActivityRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity [Roll Forward]", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Restricted Stock Units Activity" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r271" ] }, "us-gaap_CommercialPaperAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Commercial paper value listed as cash equivalent", "label": "Commercial Paper, at Carrying Value", "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested or expected to vest at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r271" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r217", "r218", "r219", "r220", "r246", "r363", "r392", "r414", "r415", "r466", "r468", "r470", "r471", "r476", "r486", "r487", "r501", "r505", "r511", "r518", "r645", "r658", "r659", "r660", "r661", "r662", "r663" ] }, "itci_CollaborativeAgreementUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "CollaborativeAgreementUpfrontPayments", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Company made an upfront payment", "label": "Collaborative Agreement Upfront Payments", "documentation": "Collaborative Agreement Upfront Payments" } } }, "auth_ref": [] }, "itci_PossibleMilestonePaymentsRemaining": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "PossibleMilestonePaymentsRemaining", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of milestone amount", "label": "Possible Milestone Payments Remaining", "documentation": "Payment of milestone amount." } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r164", "r507", "r646", "r666", "r667" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r121", "r122", "r231", "r234", "r332", "r495", "r496" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r49", "r52", "r53", "r69", "r425", "r442", "r463", "r464", "r516", "r529", "r626", "r638", "r653", "r670" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r64" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r483" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r370", "r377", "r516" ] }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteeObligationsCurrentCarryingValue", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Guarantor obligations, value", "label": "Guarantor Obligations, Current Carrying Value", "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees." } } }, "auth_ref": [ "r221" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r12" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r28" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds of public offering, net", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r307", "r308", "r311" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r40", "r78" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock outstanding, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r336", "r337", "r338", "r503", "r504", "r508", "r509", "r510" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue", "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r647" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Right of use assets under operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r327", "r515" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r63" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r103", "r490", "r516" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r59", "r82", "r149", "r155", "r159", "r161", "r369", "r378", "r500" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Assets measured using quoted prices", "verboseLabel": "Available-for-sale investment securities", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r40" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities measured using quoted prices", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r40" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Right of use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r321" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r620" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r531" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r29", "r31", "r42", "r43", "r164" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate related fair value of investments with unrealized losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r84", "r208", "r502" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r574" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r164", "r606" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government Agency Securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r497", "r508", "r665" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r531" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r5" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r575" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r531" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r306", "r312" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r573" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r18", "r516" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r531" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenues, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r150", "r151", "r154", "r157", "r158", "r162", "r163", "r164", "r237", "r238", "r364" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r40", "r41" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r573" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r128", "r129", "r130", "r131", "r132", "r139", "r141", "r142", "r143", "r147", "r304", "r305", "r368", "r384", "r498" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r308", "r336", "r337", "r338", "r503", "r504", "r508", "r509", "r510" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r28" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r573" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services (in shares)", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued employee benefits", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r312" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r568" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of anti-dilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r144" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r568" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share)", "periodEndLabel": "Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r263", "r264" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r72", "r215", "r216", "r484", "r640" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of Deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r8", "r523", "r524", "r525", "r526" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r591" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r600" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of year, Number of Shares (in shares)", "periodEndLabel": "Outstanding at end of year, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r263", "r264" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r5" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation costs related to unvested RSUs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r651" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r572" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Time based RSU's vested, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r267" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r94", "r123", "r124", "r125", "r127", "r133", "r135", "r199", "r200", "r281", "r282", "r283", "r286", "r287", "r296", "r298", "r299", "r301", "r303", "r393", "r395", "r406", "r670" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of stock options and issuances of restricted stock (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r11", "r48", "r49", "r74" ] }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposits", "label": "Certificates of Deposit, at Carrying Value", "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [ "r619" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r601" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r619", "r625" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Time based RSU's vested, Weighted-Average Grant Date Fair Value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r267" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Options exercised, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r48", "r49", "r74", "r260" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r572" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r600" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r572" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r531" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r602" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Options canceled or expired, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r649" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r94", "r110", "r111", "r112", "r123", "r124", "r125", "r127", "r133", "r135", "r148", "r199", "r200", "r236", "r281", "r282", "r283", "r286", "r287", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r314", "r316", "r317", "r318", "r319", "r320", "r331", "r393", "r394", "r395", "r406", "r462" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r15" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r601" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r58", "r102", "r374", "r397", "r398" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r573" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Comprehensive (Loss) Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r10", "r24", "r297", "r300", "r331", "r393", "r394", "r621", "r622", "r623", "r627", "r628", "r629" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r201", "r202", "r203", "r204", "r205", "r207", "r210", "r211", "r233", "r235", "r302", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r382", "r502", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r634", "r635", "r636", "r637" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r573" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r86", "r93", "r134", "r135", "r153", "r285", "r288", "r385" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r573" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r46", "r76", "r400", "r401" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r603" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Securities", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r610", "r611", "r631" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r534", "r604" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r573" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r531" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r650" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r591" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r37" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r115", "r128", "r129", "r130", "r131", "r132", "r137", "r139", "r141", "r142", "r143", "r147", "r304", "r305", "r368", "r384", "r498" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r65" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r545", "r553", "r563", "r580", "r588", "r592", "r600" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r534", "r604" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued employee benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PurchaseCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment", "label": "Purchase Commitment [Member]", "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments." } } }, "auth_ref": [ "r47", "r80" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period, Number of Shares (in shares)", "periodEndLabel": "Outstanding at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r255", "r256" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r591" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r27", "r65", "r118" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share)", "periodEndLabel": "Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r255", "r256" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r534", "r604" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r257" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized (Losses)", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r257" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities, available for sale, noncurrent", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r99", "r167", "r206" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r591" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r70", "r491" ] }, "itci_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "RoyaltyPaymentPercentage", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty payment, percentage (as a percent)", "label": "Royalty Payment Percentage", "documentation": "Royalty Payment Percentage" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r567" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r170", "r206", "r365", "r632" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r70", "r492" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Notes/Bonds", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r508", "r510", "r668" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r544", "r555", "r565", "r590" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r49" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r233", "r235", "r302", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r382", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r634", "r635", "r636", "r637" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r172" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r531" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleofInventoryCurrentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r70", "r493" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r592" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Product sales, net", "terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r506" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r535", "r546", "r556", "r581" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r593" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r568" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r248", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r591" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r591" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r49", "r423" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r248", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r49", "r423", "r442", "r670", "r671" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r592" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Time based RSU's granted, Weighted-Average Grant Date Fair Value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r266" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r535", "r546", "r556", "r581" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Time based RSU's granted, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r266" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Time based RSU's cancelled, Number of Shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r268" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r214", "r447" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r213", "r214", "r447" ] }, "itci_ThreeMajorWholesalersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "ThreeMajorWholesalersMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Three Major Wholesalers", "label": "Three Major Wholesalers [Member]", "documentation": "Three Major Wholesalers" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r61", "r446" ] }, "itci_InventoriableCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "InventoriableCostsMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Inventoriable costs", "label": "Inventoriable Costs [Member]", "documentation": "InventoriableCostsMember." } } }, "auth_ref": [] }, "itci_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Policy Text Block]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quantitative Information About Operating Leases", "label": "Schedule of Quantitative Information About Operating Leases [Table Text Block]", "documentation": "Schedule of Quantitative Information About Operating Leases" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r540", "r551", "r561", "r586" ] }, "itci_RightOfUseAssetsAndLeaseLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "RightOfUseAssetsAndLeaseLiabilitiesTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Right of Use Assets and Lease Liabilities", "label": "Right Of Use Assets And Lease Liabilities [Text Block]", "documentation": "Right of use assets and lease liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r624" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "itci_CollaborativeArrangementAmountPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "CollaborativeArrangementAmountPayable", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Obliged to make milestone payments", "label": "Collaborative Arrangement Amount Payable", "documentation": "Collaborative arrangement amount payable." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "itci_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "SignificantAccountingPoliciesTable", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "itci_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due after Year Four", "documentation": "Lessee operating lease liability payments due after Year four." } } }, "auth_ref": [] }, "itci_AccruedCustomerProgramsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "AccruedCustomerProgramsCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued customer programs", "label": "Accrued Customer Programs Current", "documentation": "Accrued customer programs current." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r6", "r35" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r323", "r515" ] }, "itci_BristolMyersSquibbCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "BristolMyersSquibbCompanyMember", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Bristol-Myers Squibb Company", "label": "Bristol Myers Squibb Company [Member]", "documentation": "Bristol Myers Squibb company." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r325", "r515" ] }, "itci_MichaelIHalsteadMember": { "xbrltype": "domainItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "MichaelIHalsteadMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Michael I. Halstead [Member]", "documentation": "Michael I. Halstead" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r324", "r515" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r51", "r74", "r375", "r396", "r398", "r404", "r424", "r516" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r326", "r515" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r37" ] }, "itci_CostOfProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.intracellulartherapies.com/20230930", "localname": "CostOfProductSales", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of product sales", "label": "Cost Of Product Sales", "documentation": "Cost of product sales." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r38", "r39", "r249" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r539", "r550", "r560", "r585" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r30", "r164" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r543", "r554", "r564", "r589" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r117" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r117" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Share-Based Payment Arrangement, Option [Member]", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r123", "r124", "r125", "r148", "r364", "r402", "r408", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r522" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive gain (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShareCommonStockEquivalentsExcludedinCalculationofDilutedLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r28" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r149", "r155", "r159", "r161", "r500" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r485", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r485", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r541", "r552", "r562", "r587" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on investment securities", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r4", "r9", "r77" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r95", "r105", "r108", "r116", "r120", "r126", "r134", "r135", "r149", "r155", "r159", "r161", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r289", "r292", "r293", "r305", "r313", "r369", "r379", "r405", "r444", "r460", "r461", "r500", "r513", "r514", "r528", "r623", "r643" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r49" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r519", "r520", "r521", "r523", "r524", "r525", "r526", "r627", "r628", "r652", "r669", "r670" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r45", "r284", "r664" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Time based RSU's cancelled, Weighted-Average Grant Date Fair Value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r268" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r50" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryofInformationRegardingtheTimeBasedRSUActivityandChangesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value Per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average discount rate (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r329", "r515" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r87", "r372", "r407", "r431", "r516", "r529", "r619" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r17", "r55", "r56", "r57" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets [Line Items]", "label": "Operating Leased Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r465", "r467", "r469", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r521" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r330" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOperatingLeasedAssetsTable", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r21", "r97", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r291", "r294", "r295", "r313", "r516", "r643", "r656", "r657" ] }, "stpr_NY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "NY", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK", "label": "NEW YORK" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r71" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r247", "r251", "r278", "r279", "r280", "r512" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r162", "r364", "r386", "r387", "r388", "r389", "r390", "r391", "r488", "r506", "r517", "r609", "r641", "r642", "r646", "r666" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r62", "r152" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of cash held in commercial paper, government securities", "label": "US Government Agencies Securities, at Carrying Value", "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Year ending December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Three months ending December 31, 2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r655" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Maturity Analysis Under Lease Agreements", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r655" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r162", "r364", "r386", "r387", "r388", "r389", "r390", "r391", "r488", "r506", "r517", "r609", "r641", "r642", "r646", "r666" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r212" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Information Regarding RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r598" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r572" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r595" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r571" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r594" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r570" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r599" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r483" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r596" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r570" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r597" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r542", "r553", "r563", "r588" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r399", "r483" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r598" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r578" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r578" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r571" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r577" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r330" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r598" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r579" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r13", "r14", "r36" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r600" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r571" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r576" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r571" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r599" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r322" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r60", "r67", "r83", "r95", "r105", "r108", "r112", "r120", "r126", "r128", "r129", "r130", "r131", "r134", "r135", "r140", "r149", "r155", "r159", "r161", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r305", "r313", "r380", "r444", "r460", "r461", "r500", "r527", "r643" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r599" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r572" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "negatedTerseLabel": "Less: Current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r322" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r599" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r572" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r19", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r291", "r294", "r295", "r313", "r422", "r499", "r529", "r643", "r656", "r657" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r232", "r240", "r245", "r308", "r336", "r508", "r509", "r510" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r599" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r79", "r101", "r120", "r149", "r156", "r160", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r290", "r294", "r313", "r371", "r436", "r516", "r529", "r643", "r644", "r656" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r232", "r240", "r245", "r308", "r337", "r503", "r504", "r508", "r509", "r510" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r232", "r240", "r241", "r242", "r243", "r244", "r245", "r308", "r338", "r503", "r504", "r508", "r509", "r510" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesMaturityanalysisundertheleaseagreementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Operating lease liabilities, non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r322" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r44", "r90" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r136", "r144", "r145", "r146" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r409", "r410", "r411", "r412", "r413", "r465", "r467", "r469", "r472", "r473", "r474", "r475", "r477", "r478", "r479", "r480", "r481", "r521" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r25", "r107", "r109", "r114", "r367", "r383" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at end of period, Weighted-Average Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r75" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r29", "r31", "r42", "r43", "r164", "r483", "r607" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/FairValueMeasurementsScheduleofFairValueMeasurementsofCashEquivalentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r307", "r308", "r311" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r543", "r554", "r564", "r589" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r165", "r166" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r580" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r27", "r98", "r489" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r545", "r553", "r563", "r580", "r588", "r592", "r600" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of premiums and accretion of discounts on investment securities, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r67" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Continuous unrealized losses, value remaining", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r85", "r209", "r502" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of investments with unrealized losses", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r85", "r209", "r502" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r96", "r104", "r120", "r198", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r290", "r294", "r313", "r516", "r643", "r644", "r656" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of long term lease", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r654" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VehiclesMember", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicle Lease", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.intracellulartherapies.com/role/RightofUseAssetsandLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r328", "r515" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Investment securities, available-for-sale", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r167", "r206" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofOperations", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r123", "r124", "r125", "r148", "r364", "r402", "r408", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r426", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r443", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r522" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.intracellulartherapies.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r306" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "calculation": { "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.intracellulartherapies.com/role/InvestmentSecuritiesSummaryofInvestmentSecuritiesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r633" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r533" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r580" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r566" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r580" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r22", "r94", "r110", "r111", "r112", "r123", "r124", "r125", "r127", "r133", "r135", "r148", "r199", "r200", "r236", "r281", "r282", "r283", "r286", "r287", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r314", "r316", "r317", "r318", "r319", "r320", "r331", "r393", "r394", "r395", "r406", "r462" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.intracellulartherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r121", "r122", "r231", "r234", "r332", "r494", "r496" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r281", "r282", "r283", "r406", "r627", "r628", "r629", "r652", "r670" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r580" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 59 0001628280-23-036217-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-036217-xbrl.zip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end